CD28	B-protein
costimulation	O
augments	O
IL-2	B-protein
secretion	O
of	O
activated	O
lamina	O
propria	O
T	O
cells	O
by	O
increasing	O
mRNA	O
stability	O
without	O
enhancing	O
IL-2	B-protein
gene	O
transactivation	O
.	O

The	O
pathways	O
leading	O
to	O
activation	O
in	O
lamina	B-cell_type
propria	I-cell_type
(	I-cell_type
LP	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
are	O
different	O
from	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

LP	B-cell_type
T	I-cell_type
cells	I-cell_type
exhibit	O
enhanced	O
IL-2	B-protein
secretion	O
when	O
activated	O
through	O
the	O
CD2	B-protein
pathway	O
.	O

Coligation	O
of	O
CD28	B-protein
leads	O
to	O
synergistic	O
enhancement	O
of	O
IL-2	B-protein
secretion	O
.	O

Previous	O
studies	O
have	O
characterized	O
the	O
CD28	B-protein
augmentation	O
of	O
TCR	B-protein
-mediated	O
signaling	O
in	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
through	O
transcriptional	O
activation	O
of	O
an	O
IL-2	B-protein
promoter	O
CD28	B-DNA
response	I-DNA
element	I-DNA
(	O
CD28RE	B-DNA
)	O
,	O
along	O
with	O
enhanced	O
mRNA	O
stability	O
.	O

This	O
study	O
characterized	O
molecular	O
events	O
involved	O
in	O
CD28	B-protein
costimulation	O
of	O
IL-2	B-protein
production	O
in	O
LP	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	I-cell_type
LPMC	I-cell_type
)	I-cell_type
.	O

LPMC	B-cell_type
exhibited	O
increased	O
IL-2	B-protein
production	O
in	O
response	O
to	O
CD28	B-protein
costimulation	O
,	O
compared	O
with	O
cells	O
activated	O
through	O
CD2	B-protein
alone	O
.	O

IL-2	B-protein
secretion	O
was	O
paralleled	O
by	O
increased	O
expression	O
of	O
IL-2	B-RNA
mRNA	I-RNA
,	O
resulting	O
from	O
enhanced	O
IL-2	B-RNA
mRNA	I-RNA
stability	O
.	O

In	O
contrast	O
to	O
transcriptional	O
activation	O
in	O
PBMC	B-cell_type
,	O
EMSA	O
revealed	O
that	O
CD28	B-protein
coligation	O
of	O
CD2-activated	B-cell_type
LPMC	I-cell_type
does	O
not	O
result	O
in	O
increased	O
binding	O
of	O
trans-factors	O
to	O
the	O
CD28RE	B-DNA
,	O
nor	O
did	O
Western	O
blots	O
detect	O
changes	O
in	O
I-kappaBalpha	B-protein
or	O
I-kappaBbeta	B-protein
levels	O
following	O
CD28	B-protein
coligation	O
.	O

Furthermore	O
,	O
CD28	B-protein
coligation	O
fails	O
to	O
enhance	O
IL-2	B-DNA
promoter-reporter	I-DNA
or	O
RE/AP	B-protein
construct	O
expression	O
in	O
CD2-activated	B-cell_type
LPMC	I-cell_type
.	O

The	O
results	O
reported	O
herein	O
indicate	O
that	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
CD28	B-protein
cosignaling	O
and	O
regulation	O
of	O
IL-2	B-protein
secretion	O
in	O
LP	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
unique	O
to	O
that	O
compartment	O
and	O
differ	O
from	O
those	O
seen	O
in	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

These	O
observations	O
suggest	O
a	O
biological	O
significance	O
for	O
different	O
mechanisms	O
of	O
IL-2	B-protein
activation	O
in	O
initiation	O
and	O
maintenance	O
of	O
the	O
cytokine	B-protein
repertoire	I-protein
found	O
in	O
the	O
mucosa	O
.	O

'_9	NULL
Analytes	NULL
=	NULL
Comprehensive	NULL
Analysis	NULL
n	NULL
MICFOVUG	NULL
Wim	NULL
Ba	NULL
,	NULL
Bb	NULL
,	NULL
C3a	NULL
,	NULL
C4a	NULL
,	NULL
C4d	NULL
,	NULL
CSa	NULL
,	NULL
s	NULL
SCS5b-9	NULL
,	NULL
Factor	NULL
H	NULL
,	NULL
Factor	NULL
|	NULL
QUIpEL	NULL
MULTIPLEX	NULL
I	NULL
ill	NULL
``	NULL
``	NULL
A	NULL
SE	NULL
ty	NULL
ay	NULL
#	NULL
m	NULL
meJournal	NULL
of	NULL
CD28	NULL
Costimulation	NULL
Augments	NULL
IL-2	NULL
1-	NULL
%	NULL
-	NULL
:	NULL
'Immun010	NULL
gy	NULL
Secretion	NULL
of	NULL
Activated	NULL
Lamina	NULL
Propria	NULL
T	NULL
Cells	NULL
by	NULL
Increasing	NULL
mRNA	NULL
Stability	NULL
Without	NULL
Enhancing	NULL
IL-2	NULL
Gene	NULL
Transactivation	NULL
\ge	NULL
?	NULL

u	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Rivkah	NULL
Gonsky	NULL
,	NULL
Richard	NULL
L.	NULL
Deem	NULL
,	NULL
Doo	NULL
Han	NULL
Lee	NULL
,	NULL
Alice	NULL
Chen	NULL
and	NULL
Stephan	NULL
R.	NULL
Targan	NULL
J	NULL
Immunol	NULL
1999	NULL
;	NULL
162:6621-6629	NULL
;	NULL
;	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/162/11/6621	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
36	NULL
articles	NULL
,	NULL
24	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/162/11/6621	NULL
.	NULL

full	NULL
#	NULL
ref-list-1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
CD28	NULL
Costimulation	NULL
Augments	NULL
IL-2	NULL
Secretion	NULL
of	NULL
Activated	NULL
Lamina	NULL
Propria	NULL
T	NULL
Cells	NULL
by	NULL
Increasing	NULL
mRNA	NULL
Stability	NULL
Without	NULL
Enhancing	NULL
IL-2	NULL
Gene	NULL
Transactivation	NULL
Rivkah	NULL
Gonsky	NULL
,	NULL
*	NULL
Richard	NULL
L.	NULL
Deem	NULL
,	NULL
*	NULL
Doo	NULL
Han	NULL
Lee	NULL
,	NULL
``	NULL
Alice	NULL
Chen	NULL
,	NULL
*	NULL
and	NULL
Stephan	NULL
R.	NULL
Targan	NULL
``	NULL
*	NULL
The	NULL
pathways	NULL
leading	NULL
to	NULL
activation	NULL
in	NULL
lamina	NULL
propria	NULL
(	NULL
LP	NULL
)	NULL
T	NULL
cells	NULL
are	NULL
different	NULL
from	NULL
peripheral	NULL
T	NULL
cells	NULL
.	NULL

LP	NULL
T	NULL
cells	NULL
exhibit	NULL
enhanced	NULL
IL-2	NULL
secretion	NULL
when	NULL
activated	NULL
through	NULL
the	NULL
CD2	NULL
pathway	NULL
.	NULL

Coligation	NULL
of	NULL
CD28	NULL
leads	NULL
to	NULL
synergistic	NULL
enhancement	NULL
of	NULL
IL-2	NULL
secretion	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
characterized	NULL
the	NULL
CD28	NULL
augmentation	NULL
of	NULL
TCR-mediated	NULL
signaling	NULL
in	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
through	NULL
transcriptional	NULL
activation	NULL
of	NULL
an	NULL
IL-2	NULL
promoter	NULL
CD28	NULL
response	NULL
element	NULL
(	NULL
CD28RE	NULL
)	NULL
,	NULL
along	NULL
with	NULL
enhanced	NULL
mRNA	NULL
stability	NULL
.	NULL

This	NULL
study	NULL
characterized	NULL
molecular	NULL
events	NULL
involved	NULL
in	NULL
CD28	NULL
costimulation	NULL
of	NULL
IL-2	NULL
production	NULL
in	NULL
LP	NULL
mononuclear	NULL
cells	NULL
(	NULL
LPMC	NULL
)	NULL
.	NULL

LPMC	NULL
exhibited	NULL
increased	NULL
IL-2	NULL
production	NULL
in	NULL
response	NULL
to	NULL
CD28	NULL
costimulation	NULL
,	NULL
compared	NULL
with	NULL
cells	NULL
activated	NULL
through	NULL
CD2	NULL
alone	NULL
.	NULL

IL-2	NULL
secretion	NULL
was	NULL
paralleled	NULL
by	NULL
increased	NULL
expression	NULL
of	NULL
IL-2	NULL
mRNA	NULL
,	NULL
resulting	NULL
from	NULL
enhanced	NULL
IL-2	NULL
mRNA	NULL
stability	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
transcriptional	NULL
activation	NULL
in	NULL
PBMC	NULL
,	NULL
EMSA	NULL
revealed	NULL
that	NULL
CD28	NULL
coligation	NULL
of	NULL
CD2-activated	NULL
LPMC	NULL
does	NULL
not	NULL
result	NULL
in	NULL
increased	NULL
binding	NULL
of	NULL
trans-factors	NULL
to	NULL
the	NULL
CD28RE	NULL
,	NULL
nor	NULL
did	NULL
Western	NULL
blots	NULL
detect	NULL
changes	NULL
in	NULL
I-xBa	NULL
or	NULL
I-BB	NULL
levels	NULL
following	NULL
CD28	NULL
coligation	NULL
.	NULL

Furthermore	NULL
,	NULL
CD28	NULL
coligation	NULL
fails	NULL
to	NULL
enhance	NULL
IL-2	NULL
promoter-reporter	NULL
or	NULL
RE/AP	NULL
construct	NULL
expression	NULL
in	NULL
CD2-activated	NULL
LPMC	NULL
.	NULL

The	NULL
results	NULL
reported	NULL
herein	NULL
indicate	NULL
that	NULL
the	NULL
molecular	NULL
mechanisms	NULL
involved	NULL
in	NULL
CD28	NULL
cosignaling	NULL
and	NULL
regulation	NULL
of	NULL
IL-2	NULL
secretion	NULL
in	NULL
LP	NULL
T	NULL
cells	NULL
are	NULL
unique	NULL
to	NULL
that	NULL
compartment	NULL
and	NULL
differ	NULL
from	NULL
those	NULL
seen	NULL
in	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
.	NULL

These	NULL
observations	NULL
suggest	NULL
a	NULL
biological	NULL
significance	NULL
for	NULL
different	NULL
mechanisms	NULL
of	NULL
IL-2	NULL
activation	NULL
in	NULL
initiation	NULL
and	NULL
maintenance	NULL
of	NULL
the	NULL
cytokine	NULL
repertoire	NULL
found	NULL
in	NULL
the	NULL
mucosa	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
1999	NULL
,	NULL
162	NULL
:	NULL
6621-6629.	NULL
role	NULL
in	NULL
initiation	NULL
and	NULL
regulation	NULL
of	NULL
cellular	NULL
immune	NULL
responses	NULL
.	NULL

Evidence	NULL
indicates	NULL
that	NULL
regulation	NULL
of	NULL
IL-2	NULL
expression	NULL
by	NULL
PBMC	NULL
takes	NULL
place	NULL
largely	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcriptional	NULL
regulation	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
has	NULL
been	NULL
extensively	NULL
studied	NULL
in	NULL
PBMC	NULL
and	NULL
T	NULL
cell	NULL
lines	NULL
following	NULL
TCR	NULL
activation	NULL
(	NULL
1	NULL
)	NULL
.	NULL

The	NULL
300-bp	NULL
promoter	NULL
region	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
upstream	NULL
of	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
contains	NULL
multiple	NULL
binding	NULL
sites	NULL
for	NULL
transcriptional	NULL
activating	NULL
factors	NULL
including	NULL
NF-AT	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
AP-1	NULL
and	NULL
OCT-binding	NULL
proteins	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Cooperative	NULL
binding	NULL
of	NULL
these	NULL
trans-acting	NULL
factors	NULL
appears	NULL
to	NULL
determine	NULL
the	NULL
balance	NULL
of	NULL
transcriptional	NULL
activation	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
transcriptional	NULL
regulation	NULL
of	NULL
IL-2	NULL
mRNA	NULL
levels	NULL
,	NULL
an	NULL
inducible	NULL
degradation	NULL
mechanism	NULL
has	NULL
been	NULL
reported	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

Production	NULL
of	NULL
IL-2	NULL
can	NULL
be	NULL
enhanced	NULL
markedly	NULL
by	NULL
treatment	NULL
with	NULL
translational	NULL
inhibitors	NULL
such	NULL
as	NULL
cycloheximide	NULL
without	NULL
directly	NULL
affecting	NULL
the	NULL
rate	NULL
of	NULL
IL-2	NULL
transcription	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Maximal	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
requires	NULL
two	NULL
signals	NULL
,	NULL
the	NULL
first	NULL
of	NULL
which	NULL
is	NULL
generated	NULL
by	NULL
engagement	NULL
of	NULL
the	NULL
TCR	NULL
,	NULL
with	NULL
a	NULL
second	NULL
signal	NULL
provided	NULL
by	NULL
a	NULL
costimulatory	NULL
molecule	NULL
.	NULL

One	NULL
major	NULL
costimulatory	NULL
T	NULL
cell	NULL
surface	NULL
molecule	NULL
is	NULL
€D28	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
.	NULL

IL-2	NULL
expression	NULL
by	NULL
I	NULL
L-2	NULL
is	NULL
secreted	NULL
by	NULL
activated	NULL
T	NULL
cells	NULL
and	NULL
plays	NULL
an	NULL
important	NULL
*Inflammatory	NULL
Bowel	NULL
Disease	NULL
Research	NULL
Center	NULL
,	NULL
Cedars-Sinai	NULL
Medical	NULL
Center	NULL
,	NULL
Los	NULL
Angeles	NULL
,	NULL
CA	NULL
90048	NULL
;	NULL
and	NULL
*	NULL
Seoul	NULL
Surgical	NULL
Clinic	NULL
Banpo-4-dong	NULL
57-3	NULL
,	NULL
Seochogu	NULL
,	NULL
Scoul	NULL
,	NULL
Korea	NULL
Received	NULL
for	NULL
publication	NULL
August	NULL
19	NULL
,	NULL
1998	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
March	NULL
16	NULL
,	NULL
1999	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
adverfisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact..	NULL
'	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
U.S.	NULL
Public	NULL
Health	NULL
Service	NULL
Grants	NULL
DK-43211	NULL
and	NULL
DK-46763	NULL
and	NULL
by	NULL
Cedars	NULL
Sinai	NULL
Medical	NULL
Center	NULL
IBD	NULL
Research	NULL
Funds	NULL
.	NULL

?	NULL

Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Stephan	NULL
R.	NULL
Targan	NULL
,	NULL
Inflammatory	NULL
Bowel	NULL
Disease	NULL
Research	NULL
Center	NULL
,	NULL
Cedars-Sinai	NULL
Medical	NULL
Center	NULL
,	NULL
8700	NULL
Beverly	NULL
Boulevard	NULL
,	NULL
D4063	NULL
,	NULL
Los	NULL
Angeles	NULL
,	NULL
CA	NULL
90048	NULL
.	NULL

Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
CD28	NULL
costimulated	NULL
peripheral	NULL
blood	NULL
(	NULL
PB	NULL
)	NULL
``	NULL
lymphocytes	NULL
is	NULL
mediated	NULL
transcriptionally	NULL
as	NULL
well	NULL
as	NULL
posttranscriptionally	NULL
.	NULL

CD28	NULL
costimulation	NULL
activates	NULL
transcription	NULL
of	NULL
IL-2	NULL
through	NULL
the	NULL
binding	NULL
of	NULL
«	NULL
B-like	NULL
transcription	NULL
factors	NULL
to	NULL
a	NULL
promoter	NULL
motif	NULL
defined	NULL
as	NULL
the	NULL
CD28	NULL
response	NULL
element	NULL
(	NULL
CD28RE	NULL
)	NULL
(	NULL
8	NULL
)	NULL
.	NULL

The	NULL
Rel	NULL
family	NULL
of	NULL
proteins	NULL
,	NULL
p50	NULL
,	NULL
p65	NULL
,	NULL
and	NULL
c-Rel	NULL
,	NULL
are	NULL
components	NULL
of	NULL
the	NULL
transcriptional	NULL
complex	NULL
binding	NULL
to	NULL
the	NULL
CD28RE	NULL
in	NULL
PBMC	NULL
(	NULL
9	NULL
)	NULL
.	NULL

A	NULL
major	NULL
component	NULL
of	NULL
regulation	NULL
of	NULL
«	NULL
B-like	NULL
transcription	NULL
factors	NULL
is	NULL
the	NULL
control	NULL
of	NULL
their	NULL
intercellular	NULL
localization	NULL
.	NULL

«	NULL
B-like	NULL
transcription	NULL
factors	NULL
are	NULL
normally	NULL
shielded	NULL
within	NULL
the	NULL
cytoplasm	NULL
through	NULL
their	NULL
physical	NULL
interaction	NULL
with	NULL
the	NULL
-B	NULL
inhibitory	NULL
protein	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

T	NULL
cell	NULL
activation	NULL
results	NULL
in	NULL
the	NULL
rapid	NULL
and	NULL
transient	NULL
decrease	NULL
of	NULL
I-	NULL
«	NULL
B	NULL
,	NULL
thereby	NULL
releasing	NULL
the	NULL
transcriptionally	NULL
active	NULL
«	NULL
B	NULL
factors	NULL
and	NULL
increasing	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

CD28-mediated	NULL
IL-2	NULL
gene	NULL
expression	NULL
in	NULL
PBMC	NULL
is	NULL
regulated	NULL
likewise	NULL
by	NULL
stabilization	NULL
of	NULL
IL-2	NULL
mRNA	NULL
.	NULL

The	NULL
IL-2	NULL
mRNA	NULL
possesses	NULL
AU-rich	NULL
sequences	NULL
within	NULL
the	NULL
3	NULL
'	NULL
untranslated	NULL
region	NULL
identified	NULL
as	NULL
the	NULL
target	NULL
signal	NULL
for	NULL
rapid	NULL
mRNA	NULL
degradation	NULL
(	NULL
12	NULL
)	NULL
.	NULL

While	NULL
CD28	NULL
costimulation	NULL
enhances	NULL
IL-2	NULL
mRNA	NULL
stability	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
stability	NULL
of	NULL
other	NULL
cytokines	NULL
,	NULL
no	NULL
preferential	NULL
enhancement	NULL
in	NULL
the	NULL
stability	NULL
of	NULL
c-myc	NULL
or	NULL
c-fos	NULL
was	NULL
detected	NULL
,	NULL
notwithstanding	NULL
the	NULL
presence	NULL
of	NULL
AU-rich	NULL
motifs	NULL
in	NULL
the	NULL
mRNA	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
regulation	NULL
of	NULL
IL-2	NULL
RNA	NULL
/	NULL
appears	NULL
to	NULL
be	NULL
com-plex	NULL
,	NULL
involving	NULL
specific	NULL
additional	NULL
pathways	NULL
that	NULL
may	NULL
be	NULL
sensitive	NULL
to	NULL
the	NULL
events	NULL
initiating	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
activation	NULL
pathways	NULL
of	NULL
PB	NULL
T	NULL
cells	NULL
are	NULL
different	NULL
from	NULL
those	NULL
of	NULL
lamina	NULL
propria	NULL
(	NULL
LP	NULL
)	NULL
T	NULL
cells	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
.	NULL

LP	NULL
T	NULL
cells	NULL
do	NULL
not	NULL
respond	NULL
well	NULL
to	NULL
activation	NULL
via	NULL
the	NULL
TCR/CD3	NULL
receptor	NULL
.	NULL

However	NULL
,	NULL
they	NULL
do	NULL
exhibit	NULL
increased	NULL
proliferation	NULL
and	NULL
cytokine	NULL
production	NULL
when	NULL
activated	NULL
via	NULL
the	NULL
CD2	NULL
pathway	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

CD28	NULL
coligation	NULL
further	NULL
enhances	NULL
the	NULL
activation	NULL
of	NULL
LP	NULL
T	NULL
cells	NULL
.	NULL

LP	NULL
T	NULL
cells	NULL
are	NULL
generally	NULL
°	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
PB	NULL
,	NULL
peripheral	NULL
blood	NULL
;	NULL
LP	NULL
,	NULL
lamina	NULL
propria	NULL
;	NULL
LPMC	NULL
,	NULL
LP	NULL
mononuclear	NULL
cells	NULL
;	NULL
UC	NULL
,	NULL
ulcerative	NULL
colitis	NULL
;	NULL
CD	NULL
,	NULL
Crohn	NULL
's	NULL
disease	NULL
;	NULL
CD28RE	NULL
,	NULL
CD28	NULL
response	NULL
element	NULL
.	NULL

0022-1767/99/	NULL
$	NULL
02.00	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
6622	NULL
thought	NULL
to	NULL
achieve	NULL
a	NULL
more	NULL
intense	NULL
activation	NULL
state	NULL
than	NULL
PB	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
intensity	NULL
can	NULL
be	NULL
amplified	NULL
further	NULL
as	NULL
has	NULL
been	NULL
demonstrated	NULL
in	NULL
conditions	NULL
of	NULL
dysregulated	NULL
inflammation	NULL
such	NULL
as	NULL
Crohn	NULL
's	NULL
disease	NULL
(	NULL
CD	NULL
)	NULL
and	NULL
ulcerative	NULL
colitis	NULL
(	NULL
UC	NULL
)	NULL
.	NULL

These	NULL
disorders	NULL
are	NULL
characterized	NULL
by	NULL
widespread	NULL
intestinal	NULL
inflammation	NULL
and	NULL
an	NULL
enhanced	NULL
T	NULL
cell	NULL
activation	NULL
state	NULL
with	NULL
increased	NULL
production	NULL
of	NULL
inflammatory	NULL
mediators	NULL
including	NULL
IL-2	NULL
(	NULL
18	NULL
)	NULL
.	NULL

We	NULL
have	NULL
developed	NULL
a	NULL
model	NULL
of	NULL
LP-like	NULL
T	NULL
cells	NULL
by	NULL
coculturing	NULL
PB	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
irradiated	NULL
Daudi	NULL
B	NULL
cells	NULL
and	NULL
IL-2	NULL
,	NULL
which	NULL
mimics	NULL
a	NULL
phenotype	NULL
of	NULL
CD2	NULL
pathway-dominant	NULL
cytokine	NULL
secretion	NULL
similar	NULL
to	NULL
that	NULL
seen	NULL
in	NULL
lamina	NULL
propria	NULL
lymphocytes	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
LP-like	NULL
T	NULL
cell	NULL
model	NULL
is	NULL
validated	NULL
by	NULL
its	NULL
functional	NULL
equivalency	NULL
to	NULL
LP	NULL
T	NULL
cells	NULL
,	NULL
not	NULL
only	NULL
with	NULL
regard	NULL
to	NULL
CD2	NULL
pathway	NULL
dominance	NULL
,	NULL
but	NULL
with	NULL
identical	NULL
phosphorylation	NULL
patterns	NULL
upon	NULL
CD2	NULL
pathway	NULL
stimulation	NULL
as	NULL
well	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
recent	NULL
studies	NULL
have	NULL
provided	NULL
evidence	NULL
that	NULL
the	NULL
LP-like	NULL
T	NULL
cell	NULL
activation	NULL
model	NULL
is	NULL
most	NULL
representative	NULL
of	NULL
the	NULL
activated	NULL
state	NULL
of	NULL
T	NULL
cells	NULL
present	NULL
in	NULL
inflamed	NULL
CD	NULL
mucosa	NULL
,	NULL
as	NULL
evidenced	NULL
by	NULL
CD2-activated	NULL
up-regulation	NULL
of	NULL
AP-1-transactivating	NULL
factors	NULL
with	NULL
similar	NULL
kinetic	NULL
profiles	NULL
(	NULL
19	NULL
)	NULL
.	NULL

The	NULL
LP-like	NULL
T	NULL
cell	NULL
model	NULL
has	NULL
very	NULL
similar	NULL
activation	NULL
properties	NULL
to	NULL
those	NULL
expressed	NULL
by	NULL
LP	NULL
mononuclear	NULL
cells	NULL
(	NULL
LPMC	NULL
)	NULL
from	NULL
inflamed	NULL
CD	NULL
mucosa	NULL
,	NULL
and	NULL
allows	NULL
investigations	NULL
of	NULL
the	NULL
mechanism	NULL
of	NULL
cytokine	NULL
gene	NULL
regulation	NULL
to	NULL
be	NULL
performed	NULL
initially	NULL
on	NULL
a	NULL
more	NULL
easily	NULL
manipulated	NULL
experimental	NULL
system	NULL
.	NULL

Little	NULL
is	NULL
known	NULL
regarding	NULL
the	NULL
underlying	NULL
mechanisms	NULL
regulating	NULL
IL-2	NULL
secretion	NULL
in	NULL
LP	NULL
T	NULL
cells	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
suggested	NULL
that	NULL
regulation	NULL
of	NULL
IL-2	NULL
production	NULL
in	NULL
LPMC	NULL
following	NULL
CD2	NULL
activation	NULL
may	NULL
involve	NULL
a	NULL
distinct	NULL
transcriptional	NULL
regulatory	NULL
mechanism	NULL
different	NULL
from	NULL
that	NULL
observed	NULL
in	NULL
T	NULL
cell	NULL
lines	NULL
(	NULL
19	NULL
)	NULL
.	NULL

The	NULL
purpose	NULL
of	NULL
this	NULL
study	NULL
was	NULL
to	NULL
determine	NULL
whether	NULL
enhanced	NULL
IL-2	NULL
secretion	NULL
by	NULL
CD2	NULL
and	NULL
CD28	NULL
costimulation	NULL
was	NULL
the	NULL
product	NULL
of	NULL
unique	NULL
events	NULL
that	NULL
regulate	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
in	NULL
LP	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
data	NULL
in	NULL
this	NULL
study	NULL
support	NULL
the	NULL
hypothesis	NULL
that	NULL
enhanced	NULL
CD28-mediated	NULL
IL-2	NULL
secretion	NULL
following	NULL
coligation	NULL
with	NULL
CD2	NULL
does	NULL
not	NULL
result	NULL
from	NULL
increased	NULL
transactivational	NULL
activity	NULL
of	NULL
the	NULL
CD28RE	NULL
or	NULL
other	NULL
elements	NULL
within	NULL
the	NULL
first	NULL
600	NULL
bp	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

The	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
molecular	NULL
mechanisms	NULL
involved	NULL
in	NULL
CD28	NULL
cosignaling	NULL
and	NULL
regulation	NULL
of	NULL
IL-2	NULL
secretion	NULL
in	NULL
LP	NULL
T	NULL
cells	NULL
are	NULL
unique	NULL
from	NULL
those	NULL
involved	NULL
in	NULL
the	NULL
peripheral	NULL
compartment	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Target	NULL
cells	NULL
and	NULL
culture	NULL
media	NULL
The	NULL
murine	NULL
T	NULL
cell	NULL
line	NULL
,	NULL
CTLL-2	NULL
,	NULL
was	NULL
obtained	NULL
from	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Manassas	NULL
,	NULL
VA	NULL
)	NULL
and	NULL
was	NULL
maintained	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
of	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
with	NULL
10	NULL
U/ml	NULL
IL-2	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
,	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
.	NULL

The	NULL
human	NULL
B	NULL
cell	NULL
line	NULL
,	NULL
Daudi	NULL
,	NULL
was	NULL
obtained	NULL
from	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
and	NULL
maintained	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
of	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

Monoclonal	NULL
Abs	NULL
Anti-CD2	NULL
mAbs	NULL
(	NULL
clones	NULL
CB6	NULL
and	NULL
GD10	NULL
)	NULL
were	NULL
a	NULL
gift	NULL
from	NULL
Chris	NULL
Benjamin	NULL
(	NULL
Biogen	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Anti-CD28	NULL
mAB	NULL
ascites	NULL
,	NULL
clone	NULL
9.3	NULL
,	NULL
was	NULL
obtained	NULL
from	NULL
Bristol-Meyers	NULL
Squibb	NULL
Pharmaceutical	NULL
Research	NULL
Institute	NULL
(	NULL
Princeton	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

The	NULL
ascites	NULL
was	NULL
purified	NULL
over	NULL
a	NULL
protein	NULL
G	NULL
column	NULL
and	NULL
quantified	NULL
by	NULL
ELISA	NULL
.	NULL

Purification	NULL
of	NULL
LPMC	NULL
and	NULL
PBMC	NULL
Intestinal	NULL
specimens	NULL
were	NULL
obtained	NULL
from	NULL
patients	NULL
undergoing	NULL
surgical	NULL
re-section	NULL
of	NULL
the	NULL
colon	NULL
(	NULL
with	NULL
colon	NULL
carcinoma	NULL
or	NULL
treatment-resistant	NULL
CD	NULL
or	NULL
UC	NULL
)	NULL
at	NULL
Cedars-Sinai	NULL
Medical	NULL
Center	NULL
,	NULL
Los	NULL
Angeles	NULL
,	NULL
CA	NULL
.	NULL

Approval	NULL
for	NULL
the	NULL
use	NULL
of	NULL
human	NULL
subjects	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
Institutional	NULL
Review	NULL
Board	NULL
at	NULL
Cedars-Sinai	NULL
Medical	NULL
Center	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
all	NULL
tissue	NULL
specimens	NULL
were	NULL
taken	NULL
from	NULL
an	NULL
uninvolved	NULL
area	NULL
of	NULL
resected	NULL
colon	NULL
from	NULL
patients	NULL
with	NULL
colonic	NULL
carcinoma	NULL
(	NULL
normal	NULL
)	NULL
,	NULL
involved	NULL
areas	NULL
of	NULL
patients	NULL
with	NULL
UC	NULL
,	NULL
as	NULL
well	NULL
as	NULL
from	NULL
uninvolved	NULL
and	NULL
involved	NULL
areas	NULL
of	NULL
patients	NULL
with	NULL
CD	NULL
.	NULL

LPMC	NULL
were	NULL
isolated	NULL
using	NULL
a	NULL
technique	NULL
modified	NULL
from	NULL
that	NULL
described	NULL
previously	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
the	NULL
TRANSACTIVATION	NULL
OF	NULL
THE	NULL
IL-2	NULL
PROMOTER	NULL
intestinal	NULL
specimen	NULL
was	NULL
washed	NULL
with	NULL
HBSS	NULL
,	NULL
and	NULL
the	NULL
mucosa	NULL
was	NULL
dissected	NULL
away	NULL
from	NULL
the	NULL
underlying	NULL
layers	NULL
.	NULL

The	NULL
mucosal	NULL
layer	NULL
was	NULL
incubated	NULL
in	NULL
a	NULL
shaking	NULL
water	NULL
bath	NULL
(	NULL
100	NULL
rpm	NULL
)	NULL
in	NULL
calcium-	NULL
and	NULL
magnesium-deficient	NULL
HBSS	NULL
,	NULL
containing	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
50	NULL
pg/ml	NULL
gentamicin	NULL
,	NULL
100	NULL
U/ml	NULL
penicillin	NULL
,	NULL
100	NULL
ug/tol	NULL
streptomycin	NULL
,	NULL
and	NULL
50	NULL
pg/ml	NULL
fungizone	NULL
,	NULL
with	NULL
the	NULL
solution	NULL
changed	NULL
every	NULL
30	NULL
min	NULL
until	NULL
the	NULL
supernatant	NULL
was	NULL
free	NULL
of	NULL
epithelial	NULL
cells	NULL
.	NULL

The	NULL
remaining	NULL
LP	NULL
was	NULL
minced	NULL
into	NULL
1-	NULL
to	NULL
2-mm	NULL
pieces	NULL
and	NULL
digested	NULL
for	NULL
10	NULL
min	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
,	NULL
0.5	NULL
mg/ml	NULL
collagenase	NULL
B	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
,	NULL
1	NULL
mg/ml	NULL
hyaluronidase	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
,	NULL
0.1	NULL
mg/ml	NULL
DNase	NULL
I	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
50	NULL
ug/ml	NULL
gentamicin	NULL
,	NULL
100	NULL
U/ml	NULL
penicillin	NULL
,	NULL
100	NULL
g/ml	NULL
streptomycin	NULL
,	NULL
and	NULL
50	NULL
pg/ml	NULL
fungizone	NULL
in	NULL
shaker	NULL
water	NULL
bath	NULL
(	NULL
100	NULL
rpm	NULL
)	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
collected	NULL
,	NULL
filtered	NULL
through	NULL
110-um	NULL
nylon	NULL
mesh	NULL
(	NULL
Spectrum	NULL
Laboratory	NULL
Products	NULL
,	NULL
Houston	NULL
,	NULL
TX	NULL
)	NULL
,	NULL
and	NULL
centrifuged	NULL
at	NULL
500	NULL
X	NULL
g	NULL
for	NULL
5	NULL
min	NULL
.	NULL

The	NULL
cell	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
15	NULL
ml	NULL
and	NULL
centrifuged	NULL
at	NULL
30	NULL
X	NULL
g	NULL
for	NULL
5	NULL
min	NULL
to	NULL
remove	NULL
epithelial	NULL
and	NULL
other	NULL
large	NULL
cells	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
removed	NULL
and	NULL
lymphocytes	NULL
were	NULL
isolated	NULL
by	NULL
separation	NULL
on	NULL
Ficoll-Hypaque	NULL
gradients	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
HBSS	NULL
and	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

PBMC	NULL
were	NULL
isolated	NULL
from	NULL
normal	NULL
healthy	NULL
volunteers	NULL
by	NULL
separation	NULL
on	NULL
Ficoll-Hypaque	NULL
gradients	NULL
.	NULL

Induction	NULL
of	NULL
LP-like	NULL
T	NULL
cells	NULL
Mononuclear	NULL
cells	NULL
from	NULL
Ficoll-Hypaque	NULL
gradients	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
with	NULL
a	NULL
1:5	NULL
ratio	NULL
Daudi	NULL
:	NULL
lymphocytes	NULL
plus	NULL
10	NULL
U/ml	NULL
rIL-2	NULL
for	NULL
5	NULL
days	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Daudi	NULL
were	NULL
irradiated	NULL
with	NULL
3000	NULL
rad	NULL
and	NULL
washed	NULL
three	NULL
times	NULL
in	NULL
HBSS	NULL
before	NULL
addition	NULL
to	NULL
cultures	NULL
.	NULL

Following	NULL
a	NULL
5-day	NULL
culture	NULL
,	NULL
LP-like	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
HBSS	NULL
to	NULL
remove	NULL
dead	NULL
Daudi	NULL
cells	NULL
(	NULL
at	NULL
this	NULL
point	NULL
,	NULL
there	NULL
were	NULL
virtually	NULL
no	NULL
live	NULL
Daudi	NULL
cells	NULL
in	NULL
the	NULL
culture	NULL
as	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
mononuclear	NULL
cells	NULL
For	NULL
stimulation	NULL
through	NULL
the	NULL
CD2	NULL
receptor	NULL
,	NULL
LPMC	NULL
and	NULL
LP-like	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
0.1	NULL
pg	NULL
anti-CD2	NULL
Abs	NULL
(	NULL
both	NULL
CB6	NULL
and	NULL
GD10	NULL
clones	NULL
)	NULL
/10®	NULL
cells	NULL
at	NULL
37°C	NULL
for	NULL
the	NULL
times	NULL
indicated	NULL
for	NULL
each	NULL
experiment	NULL
.	NULL

CD28	NULL
costimulation	NULL
was	NULL
carried	NULL
out	NULL
with	NULL
0.1	NULL
pg	NULL
anti-CD28	NULL
Ab	NULL
.	NULL

Stimulation	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
anti-CD2	NULL
Abs	NULL
did	NULL
not	NULL
require	NULL
further	NULL
cross-linking	NULL
,	NULL
since	NULL
the	NULL
combination	NULL
of	NULL
two	NULL
anti-CD2	NULL
Abs	NULL
directed	NULL
against	NULL
different	NULL
epitopes	NULL
was	NULL
sufficient	NULL
to	NULL
induce	NULL
activation	NULL
.	NULL

IL-2	NULL
bioassay	NULL
IL-2	NULL
activity	NULL
was	NULL
determined	NULL
using	NULL
a	NULL
CTLL-2	NULL
bioassay	NULL
(	NULL
21	NULL
)	NULL
.	NULL

rIL-2	NULL
standards	NULL
and	NULL
dilutions	NULL
of	NULL
samples	NULL
were	NULL
added	NULL
to	NULL
96-well	NULL
flat-bottom	NULL
microtiter	NULL
plates	NULL
(	NULL
Costar	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
containing	NULL
5	NULL
X	NULL
10°	NULL
CTLL-2/well	NULL
and	NULL
incubated	NULL
for	NULL
48	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

Wells	NULL
were	NULL
then	NULL
pulsed	NULL
with	NULL
2	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
for	NULL
4	NULL
h.	NULL
Wells	NULL
were	NULL
harvested	NULL
using	NULL
a	NULL
Harvester	NULL
96	NULL
(	NULL
Tomtec	NULL
,	NULL
Orange	NULL
,	NULL
CT	NULL
)	NULL
microplate	NULL
harvester	NULL
and	NULL
counted	NULL
using	NULL
a	NULL
Microbeta	NULL
1450	NULL
liquid	NULL
scintillation	NULL
counter	NULL
(	NULL
Wallac	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

Data	NULL
acquisition	NULL
and	NULL
analysis	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
ELISA	NULL
Master	NULL
program	NULL
for	NULL
Macintosh	NULL
computers	NULL
,	NULL
developed	NULL
by	NULL
R.	NULL
L.	NULL
Deem	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
Total	NULL
cellular	NULL
RNA	NULL
was	NULL
extracted	NULL
using	NULL
the	NULL
Qiagen	NULL
RNeasy	NULL
kit	NULL
(	NULL
Chats-worth	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

RNA	NULL
was	NULL
electrophoretically	NULL
separated	NULL
on	NULL
a	NULL
denaturing	NULL
1	NULL
%	NULL
agarose	NULL
gel	NULL
containing	NULL
7	NULL
%	NULL
formaldehyde	NULL
.	NULL

Gels	NULL
were	NULL
transferred	NULL
to	NULL
nylon	NULL
membrane	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
and	NULL
hybridized	NULL
to	NULL
*°P-la-beled	NULL
DNA	NULL
probe	NULL
.	NULL

Isolated	NULL
cDNA	NULL
insert	NULL
was	NULL
labeled	NULL
by	NULL
random	NULL
priming	NULL
and	NULL
used	NULL
at	NULL
10°	NULL
cpm/ml	NULL
of	NULL
hybridization	NULL
buffer	NULL
.	NULL

Blots	NULL
were	NULL
prehybridized	NULL
(	NULL
50	NULL
%	NULL
formamide	NULL
,	NULL
0.75	NULL
M	NULL
NaCl	NULL
,	NULL
75	NULL
mM	NULL
sodium	NULL
citrate	NULL
,	NULL
1X	NULL
Denhardt	NULL
so-lution	NULL
,	NULL
25	NULL
mM	NULL
sodium	NULL
phosphate	NULL
(	NULL
pH	NULL
6.5	NULL
)	NULL
,	NULL
and	NULL
100	NULL
pg/ml	NULL
of	NULL
sheared	NULL
salmon	NULL
sperm	NULL
DNA	NULL
)	NULL
at	NULL
42°C	NULL
for	NULL
2	NULL
h	NULL
and	NULL
hybridized	NULL
overnight	NULL
in	NULL
prehy-bridization	NULL
solution	NULL
containing	NULL
labeled	NULL
probe	NULL
and	NULL
10	NULL
%	NULL
dextran	NULL
sulfate	NULL
.	NULL

Nuclear	NULL
run-on	NULL
A	NULL
total	NULL
of	NULL
5	NULL
X	NULL
10	NULL
``	NULL
LPMC	NULL
were	NULL
stimulated	NULL
and	NULL
nuclei	NULL
isolated	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
22	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
transcription	NULL
was	NULL
carried	NULL
out	NULL
at	NULL
26°C	NULL
for	NULL
20	NULL
min	NULL
in	NULL
transcription	NULL
buffer	NULL
(	NULL
50	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
100	NULL
mM	NULL
KCI	NULL
,	NULL
2	NULL
mM	NULL
DTT	NULL
,	NULL
30	NULL
LM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
ATP	NULL
,	NULL
0.5	NULL
mM	NULL
GTP	NULL
,	NULL
0.5	NULL
mM	NULL
CTP	NULL
,	NULL
2	NULL
mM	NULL
MnCl	NULL
,	NULL
35	NULL
mM	NULL
(	NULL
NH	NULL
,	NULL
)	NULL
;	NULL
,	NULL
SO	NULL
,	NULL
,	NULL
8.8	NULL
mM	NULL
creatine	NULL
phosphate	NULL
,	NULL
40	NULL
ug/ml	NULL
creatine	NULL
phosphoki-nase	NULL
)	NULL
,	NULL
and	NULL
100	NULL
Ci	NULL
of	NULL
[	NULL
«	NULL
-*°P	NULL
]	NULL
UTP	NULL
.	NULL

Labeled	NULL
mRNA	NULL
transcripts	NULL
were	NULL
purified	NULL
using	NULL
Qiagen	NULL
Rneasy	NULL
kit	NULL
for	NULL
liquid	NULL
samples	NULL
and	NULL
hybridized	NULL
to	NULL
2	NULL
ug	NULL
of	NULL
cDNA	NULL
insert	NULL
immobilized	NULL
on	NULL
a	NULL
nylon	NULL
membrane	NULL
.	NULL

Preparation	NULL
of	NULL
nuclear	NULL
protein	NULL
extracts	NULL
Nuclear	NULL
protein	NULL
extractions	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
5	NULL
to	NULL
10	NULL
X	NULL
10°	NULL
LPMC	NULL
or	NULL
LP-like	NULL
T	NULL
cells	NULL
.	NULL

Following	NULL
activation	NULL
,	NULL
cells	NULL
were	NULL
centrifuged	NULL
,	NULL
washed	NULL
in	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
cold	NULL
PBS	NULL
,	NULL
and	NULL
kept	NULL
on	NULL
ice	NULL
for	NULL
subsequent	NULL
extraction	NULL
steps	NULL
.	NULL

The	NULL
cell	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
0.9	NULL
ml	NULL
of	NULL
RSB	NULL
(	NULL
10	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
10	NULL
mM	NULL
NaCl	NULL
,	NULL
3	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
2	NULL
wM	NULL
leupeptin	NULL
,	NULL
1	NULL
ug/ml	NULL
aprotinin	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
,	NULL
and	NULL
0.1	NULL
mM	NULL
EGTA	NULL
)	NULL
,	NULL
and	NULL
0.1	NULL
ml	NULL
of	NULL
5	NULL
%	NULL
NP-40	NULL
was	NULL
added	NULL
.	NULL

Samples	NULL
were	NULL
mixed	NULL
by	NULL
gentle	NULL
inversion	NULL
and	NULL
kept	NULL
on	NULL
ice	NULL
for	NULL
10	NULL
min	NULL
followed	NULL
by	NULL
centrifugation	NULL
.	NULL

The	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
25-60	NULL
pl	NULL
(	NULL
volume	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
starting	NULL
number	NULL
of	NULL
cells	NULL
)	NULL
of	NULL
cold	NULL
buffer	NULL
C	NULL
(	NULL
20	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
0.42	NULL
mM	NULL
NaCl	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
25	NULL
%	NULL
v/v	NULL
glycerol	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
20	NULL
mM	NULL
leupeptin	NULL
,	NULL
10	NULL
pg/ml	NULL
aprotinin	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
PMSF	NULL
)	NULL
.	NULL

Samples	NULL
were	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
30-40	NULL
min	NULL
during	NULL
which	NULL
time	NULL
they	NULL
were	NULL
pipetted	NULL
twice	NULL
.	NULL

Cellular	NULL
debris	NULL
was	NULL
removed	NULL
by	NULL
centrifugation	NULL
and	NULL
nuclear	NULL
proteins	NULL
were	NULL
diluted	NULL
with	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
buffer	NULL
D	NULL
(	NULL
20	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
50	NULL
mM	NULL
KCI	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
20	NULL
%	NULL
v/v	NULL
glycerol	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
20	NULL
mM	NULL
leupeptin	NULL
,	NULL
10	NULL
pg/ml	NULL
aprotinin	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
PMSF	NULL
)	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
determined	NULL
by	NULL
Coomassie	NULL
Plus	NULL
assay	NULL
(	NULL
Pierce	NULL
,	NULL
Rockford	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

EMSA	NULL
Double-stranded	NULL
oligonucleotide	NULL
was	NULL
end-labeled	NULL
with	NULL
[	NULL
y-*°P	NULL
]	NULL
ATP	NULL
and	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
.	NULL

A	NULL
total	NULL
of	NULL
3-6	NULL
pug	NULL
of	NULL
nuclear	NULL
extract	NULL
protein	NULL
was	NULL
incubated	NULL
at	NULL
25°C	NULL
with	NULL
0.25	NULL
mg/ml	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
,	NULL
in	NULL
20	NULL
%	NULL
glycerol	NULL
,	NULL
5	NULL
mM	NULL
MgC	NULL
]	NULL
,	NULL
2.5	NULL
mM	NULL
EDTA	NULL
,	NULL
2.5	NULL
mM	NULL
DTT	NULL
,	NULL
250	NULL
mM	NULL
NaCl	NULL
,	NULL
and	NULL
50	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
for	NULL
10	NULL
min	NULL
.	NULL

The	NULL
oligonucleotide	NULL
was	NULL
then	NULL
added	NULL
(	NULL
20,000	NULL
cpm	NULL
)	NULL
and	NULL
the	NULL
binding	NULL
reactions	NULL
were	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
30	NULL
min	NULL
.	NULL

Specificity	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
100-fold	NULL
excess	NULL
unlabeled	NULL
oligonucleotide	NULL
as	NULL
competitor	NULL
.	NULL

The	NULL
DNA-protein	NULL
complexes	NULL
were	NULL
separated	NULL
from	NULL
unbound	NULL
probe	NULL
on	NULL
a	NULL
prerun	NULL
native	NULL
5	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
low	NULL
ionic	NULL
strength	NULL
buffer	NULL
(	NULL
22.3	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
22.3	NULL
mM	NULL
borate	NULL
,	NULL
and	NULL
0.5	NULL
mM	NULL
EDTA	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
)	NULL
.	NULL

After	NULL
2	NULL
h	NULL
,	NULL
the	NULL
gel	NULL
was	NULL
dried	NULL
under	NULL
vacuum	NULL
and	NULL
exposed	NULL
to	NULL
x-ray	NULL
film	NULL
.	NULL

The	NULL
oligonucleotide	NULL
used	NULL
was	NULL
the	NULL
composite	NULL
IL-2	NULL
CD28RE/AP	NULL
site	NULL
:	NULL
(	NULL
5'-GTTTAAAGAAATTCCAAAGAGTCATCAG-3	NULL
'	NULL
)	NULL
.	NULL

Nonspecific	NULL
competitor	NULL
oligonucleotide	NULL
used	NULL
was	NULL
:	NULL
(	NULL
5-GAGCCTGATTITTCCCCGAAATGA	NULL
TGAGC-3	NULL
'	NULL
)	NULL
.	NULL

DNA	NULL
constructs	NULL
The	NULL
human	NULL
IL-2	NULL
cDNA	NULL
clone	NULL
and	NULL
B-actin	NULL
were	NULL
obtained	NULL
from	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
.	NULL

A	NULL
human	NULL
IL-2	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
containing	NULL
a	NULL
600-bp	NULL
fragment	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
subcloned	NULL
immediately	NULL
5	NULL
'	NULL
to	NULL
the	NULL
luciferase	NULL
gene	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
human	NULL
RE/AP	NULL
and	NULL
mutant	NULL
RE/AP	NULL
promoter-reporter	NULL
constructs	NULL
have	NULL
been	NULL
previously	NULL
described	NULL
(	NULL
24	NULL
)	NULL
and	NULL
were	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Virginia	NULL
Smith-Shapiro	NULL
and	NULL
Arthur	NULL
Weiss	NULL
(	NULL
University	NULL
of	NULL
California	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
plasmid	NULL
TREZ	NULL
luciferase	NULL
,	NULL
used	NULL
to	NULL
determine	NULL
AP-1-dependent	NULL
frans-activation	NULL
,	NULL
was	NULL
generated	NULL
by	NULL
subcloning	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
collagenase	NULL
AP-1	NULL
binding	NULL
sites	NULL
into	NULL
a	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
M.	NULL
Karin	NULL
)	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Transfection	NULL
Freshly	NULL
isolated	NULL
LPMC	NULL
and	NULL
PBMC	NULL
were	NULL
primed	NULL
for	NULL
transfection	NULL
competence	NULL
by	NULL
culturing	NULL
for	NULL
16	NULL
or	NULL
20	NULL
h	NULL
,	NULL
respectively	NULL
,	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
,	NULL
50	NULL
mM	NULL
2-ME	NULL
,	NULL
and	NULL
1	NULL
pg/ml	NULL
PHA-L	NULL
(	NULL
Sigma	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
19	NULL
,	NULL
23	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
washed	NULL
and	NULL
resuspended	NULL
in	NULL
250	NULL
ul	NULL
fresh	NULL
medium	NULL
at	NULL
2	NULL
X	NULL
10	NULL
``	NULL
cells/ml	NULL
and	NULL
electroporated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
50	NULL
ug	NULL
of	NULL
reporter	NULL
construct	NULL
(	NULL
250	NULL
V	NULL
,	NULL
2250	NULL
microfarads	NULL
,	NULL
48	NULL
ohms	NULL
)	NULL
using	NULL
4-mm	NULL
(	NULL
gap	NULL
width	NULL
)	NULL
cuvettes	NULL
in	NULL
a	NULL
BTX	NULL
Electro	NULL
Cell	NULL
Manipulator	NULL
(	NULL
Genetron-ics	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

After	NULL
electroporation	NULL
the	NULL
cells	NULL
were	NULL
diluted	NULL
in	NULL
fresh	NULL
medium	NULL
,	NULL
allowed	NULL
to	NULL
rest	NULL
for	NULL
1	NULL
h	NULL
prior	NULL
to	NULL
plating	NULL
,	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
anti-CD2	NULL
or	NULL
anti-CD2	NULL
+	NULL
CD28	NULL
mAbs	NULL
for	NULL
4	NULL
h.	NULL
Since	NULL
transfection	NULL
of	NULL
a	NULL
single	NULL
promoter	NULL
was	NULL
assayed	NULL
for	NULL
expression	NULL
under	NULL
different	NULL
activation	NULL
conditions	NULL
,	NULL
normalization	NULL
for	NULL
transfection	NULL
efficiency	NULL
was	NULL
not	NULL
necessary	NULL
.	NULL

However	NULL
,	NULL
multiple	NULL
transfections	NULL
with	NULL
different	NULL
preparation	NULL
of	NULL
reporter	NULL
constructs	NULL
gave	NULL
similar	NULL
results	NULL
.	NULL

Luminescence	NULL
was	NULL
measured	NULL
using	NULL
a	NULL
Promega	NULL
(	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
luciferase	NULL
assay	NULL
kit	NULL
and	NULL
counted	NULL
on	NULL
a	NULL
6-detector	NULL
Wallac	NULL
(	NULL
Gaithersberg	NULL
,	NULL
MD	NULL
)	NULL
1450	NULL
Microbeta	NULL
liquid	NULL
scintillation	NULL
counter	NULL
with	NULL
coincidence	NULL
counting	NULL
turned	NULL
off	NULL
.	NULL

Western	NULL
blotting	NULL
Samples	NULL
containing	NULL
10-15	NULL
pug	NULL
of	NULL
nuclear	NULL
protein	NULL
extracts	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
SDS-polyacrylamide	NULL
gel	NULL
(	NULL
10	NULL
%	NULL
polyacrylamide	NULL
)	NULL
and	NULL
transferred	NULL
by	NULL
electroblotting	NULL
to	NULL
nitrocellulose	NULL
membrane	NULL
(	NULL
Hybond	NULL
C	NULL
,	NULL
Amersham	NULL
)	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
blocked	NULL
for	NULL
2	NULL
h	NULL
with	NULL
5	NULL
%	NULL
nonfat	NULL
milk	NULL
in	NULL
TBS	NULL
with	NULL
0.1	NULL
%	NULL
Tween-20	NULL
and	NULL
analyzed	NULL
for	NULL
immunoreactivity	NULL
with	NULL
antisera	NULL
to	NULL
IxBa	NULL
and	NULL
IxBB	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
with	NULL
an	NULL
enhanced	NULL
chemiluminescence	NULL
detection	NULL
system	NULL
(	NULL
Pierce	NULL
)	NULL
.	NULL

6623	NULL
LPMC	NULL
LP-Like	NULL
2.0	NULL
45	NULL
-B-	NULL
CD2	NULL
ao	NULL
}	NULL
|	NULL
t-	NULL
592	NULL
,	NULL
-	NULL
@	NULL
-CD2	NULL
+	NULL
CD28	NULL
-	NULL
@	NULL
-	NULL
CD2	NULL
+	NULL
CD28	NULL
€1.5	NULL
35	NULL
3	NULL
30	NULL
e	NULL
1.0	NULL
25	NULL
x	NULL
20	NULL
H	NULL
15	NULL
-	NULL
0.5	NULL
10	NULL
5	NULL
0	NULL
o	NULL
0	NULL
5	NULL
10	NULL
15	NULL
20	NULL
25	NULL
0	NULL
5	NULL
10	NULL
15	NULL
20	NULL
25	NULL
Time	NULL
(	NULL
hr	NULL
)	NULL
Time	NULL
(	NULL
hr	NULL
)	NULL
FIGURE	NULL
1	NULL
.	NULL

Effect	NULL
of	NULL
costimulation	NULL
by	NULL
CD28	NULL
on	NULL
IL-2	NULL
secretion	NULL
in	NULL
LPMC	NULL
and	NULL
LP-like	NULL
T	NULL
cells	NULL
activated	NULL
via	NULL
the	NULL
CD2	NULL
pathway	NULL
.	NULL

A	NULL
,	NULL
LPMC	NULL
from	NULL
inflamed	NULL
mucosa	NULL
stimulated	NULL
with	NULL
1	NULL
pg	NULL
anti-CD2/10®	NULL
cells	NULL
or	NULL
1	NULL
ug	NULL
anti-CD2/10®	NULL
cells	NULL
+	NULL
1	NULL
ug	NULL
anti-CD28/10°	NULL
cells	NULL
.	NULL

B	NULL
,	NULL
PBL	NULL
cultured	NULL
5	NULL
days	NULL
in	NULL
IL-2	NULL
with	NULL
irradiated	NULL
Daudi	NULL
cells	NULL
(	NULL
LP-like	NULL
T	NULL
cells	NULL
)	NULL
prior	NULL
to	NULL
stimulation	NULL
with	NULL
anti-CD2	NULL
or	NULL
anti-CD2	NULL
+	NULL
anti-CD28	NULL
.	NULL

MBI	NULL
,	NULL
Anti-CD2	NULL
alone	NULL
;	NULL
@	NULL
,	NULL
anti-CD2	NULL
+	NULL
anti-CD28	NULL
.	NULL

Representative	NULL
of	NULL
three	NULL
experiments	NULL
with	NULL
similar	NULL
results	NULL
is	NULL
shown	NULL
.	NULL

Results	NULL
Costimulation	NULL
by	NULL
CD28	NULL
augments	NULL
IL-2	NULL
secretion	NULL
and	NULL
increases	NULL
mRNA	NULL
accumulation	NULL
in	NULL
LPMC	NULL
and	NULL
LP-like	NULL
T	NULL
cells	NULL
activated	NULL
via	NULL
the	NULL
CD2	NULL
pathway	NULL
We	NULL
have	NULL
described	NULL
previously	NULL
a	NULL
model	NULL
developed	NULL
using	NULL
in	NULL
vitro-activated	NULL
PB	NULL
T	NULL
cells	NULL
,	NULL
known	NULL
as	NULL
LP-like	NULL
T	NULL
cells	NULL
,	NULL
which	NULL
reproduce	NULL
the	NULL
CD2-driven	NULL
cytokine	NULL
secretion	NULL
phenotype	NULL
seen	NULL
in	NULL
LP	NULL
T	NULL
cells	NULL
(	NULL
16	NULL
,	NULL
19	NULL
)	NULL
.	NULL

LP	NULL
T	NULL
cells	NULL
and	NULL
LP-like	NULL
T	NULL
cells	NULL
are	NULL
significantly	NULL
more	NULL
responsive	NULL
than	NULL
PB	NULL
T	NULL
cells	NULL
to	NULL
activation	NULL
via	NULL
the	NULL
CD2	NULL
pathway	NULL
than	NULL
the	NULL
CD3	NULL
pathway	NULL
,	NULL
as	NULL
exhibited	NULL
by	NULL
the	NULL
secretion	NULL
of	NULL
IL-2	NULL
and	NULL
other	NULL
cytokines	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Coligation	NULL
of	NULL
CD2	NULL
,	NULL
but	NULL
not	NULL
CD3	NULL
,	NULL
with	NULL
CD28	NULL
resulted	NULL
in	NULL
a	NULL
marked	NULL
increase	NULL
of	NULL
IL-2	NULL
secretion	NULL
in	NULL
LPMC	NULL
and	NULL
LP-like	NULL
T	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
molecular	NULL
mechanisms	NULL
of	NULL
CD28-enhanced	NULL
IL-2	NULL
secretion	NULL
,	NULL
we	NULL
first	NULL
examined	NULL
the	NULL
kinetics	NULL
of	NULL
IL-2	NULL
production	NULL
following	NULL
activation	NULL
of	NULL
LPMC	NULL
and	NULL
LP-like	NULL
T	NULL
cells	NULL
via	NULL
the	NULL
CD2	NULL
pathway	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
CD28	NULL
costimulation	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1A	NULL
,	NULL
measurable	NULL
amounts	NULL
of	NULL
IL-2	NULL
were	NULL
detected	NULL
in	NULL
superna-tants	NULL
of	NULL
LPMC	NULL
isolated	NULL
from	NULL
inflamed	NULL
mucosa	NULL
as	NULL
early	NULL
as	NULL
3	NULL
h	NULL
following	NULL
CD2	NULL
activation	NULL
.	NULL

IL-2	NULL
levels	NULL
continued	NULL
to	NULL
increase	NULL
over	NULL
24	NULL
h.	NULL
CD28	NULL
costimulation	NULL
resulted	NULL
in	NULL
a	NULL
striking	NULL
increase	NULL
of	NULL
IL-2	NULL
production	NULL
at	NULL
all	NULL
time	NULL
points	NULL
measured	NULL
.	NULL

CD28	NULL
coligation	NULL
of	NULL
LP-like	NULL
T	NULL
cells	NULL
likewise	NULL
resulted	NULL
in	NULL
enhancement	NULL
of	NULL
IL-2	NULL
secretion	NULL
at	NULL
all	NULL
time	NULL
points	NULL
tested	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
molecular	NULL
events	NULL
associated	NULL
with	NULL
CD28-aug-mented	NULL
IL-2	NULL
production	NULL
,	NULL
mRNA	NULL
was	NULL
measured	NULL
at	NULL
time	NULL
points	NULL
following	NULL
CD2	NULL
or	NULL
CD2	NULL
+	NULL
CD28	NULL
activation	NULL
of	NULL
LPMC	NULL
and	NULL
LP-like	NULL
T	NULL
cells	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
of	NULL
IL-2	NULL
mRNA	NULL
from	NULL
LPMC	NULL
revealed	NULL
that	NULL
following	NULL
activation	NULL
by	NULL
CD2	NULL
,	NULL
cytokine	NULL
secretion	NULL
was	NULL
preceded	NULL
by	NULL
an	NULL
increased	NULL
expression	NULL
of	NULL
IL-2	NULL
mRNA	NULL
.	NULL

IL-2	NULL
mRNA	NULL
was	NULL
detectable	NULL
within	NULL
1	NULL
h	NULL
,	NULL
peaked	NULL
at	NULL
4	NULL
h	NULL
,	NULL
and	NULL
then	NULL
declined	NULL
to	NULL
barely	NULL
detectable	NULL
levels	NULL
by	NULL
6	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

CD28	NULL
costimulation	NULL
resulted	NULL
in	NULL
a	NULL
striking	NULL
elevation	NULL
of	NULL
IL-2	NULL
mRNA	NULL
expression	NULL
,	NULL
as	NULL
well	NULL
as	NULL
a	NULL
prolonged	NULL
period	NULL
of	NULL
detectability	NULL
.	NULL

The	NULL
early	NULL
kinetics	NULL
of	NULL
IL-2	NULL
mRNA	NULL
accumulation	NULL
appeared	NULL
similar	NULL
to	NULL
that	NULL
seen	NULL
with	NULL
CD2	NULL
activation	NULL
alone	NULL
.	NULL

IL-2	NULL
mRNA	NULL
was	NULL
detectable	NULL
at	NULL
1	NULL
h	NULL
following	NULL
activation	NULL
and	NULL
peaked	NULL
at	NULL
4	NULL
h.	NULL
However	NULL
,	NULL
while	NULL
no	NULL
IL-2	NULL
mRNA	NULL
was	NULL
detectable	NULL
from	NULL
the	NULL
CD2-activated	NULL
cells	NULL
at	NULL
24	NULL
h	NULL
following	NULL
activation	NULL
,	NULL
IL-2	NULL
mRNA	NULL
was	NULL
still	NULL
detectable	NULL
from	NULL
cells	NULL
costimulated	NULL
with	NULL
CD28	NULL
.	NULL

Figs	NULL
.	NULL

1B	NULL
and	NULL
2B	NULL
demonstrate	NULL
that	NULL
IL-2	NULL
secretion	NULL
and	NULL
mRNA	NULL
levels	NULL
in	NULL
the	NULL
LP-like	NULL
T	NULL
cell	NULL
model	NULL
activated	NULL
by	NULL
Abs	NULL
to	NULL
CD2	NULL
or	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
6624	NULL
A	NULL
(	NULL
hours	NULL
)	NULL
0	NULL
1	NULL
2	NULL
4	NULL
TRANSACTIVATION	NULL
OF	NULL
THE	NULL
IL-2	NULL
PROMOTER	NULL
6	NULL
24	NULL
EtBr	NULL
CD2	NULL
CD2	NULL
+	NULL
CD28	NULL
B	NULL
(	NULL
hours	NULL
)	NULL
0	NULL
$	NULL
1	NULL
2	NULL
6	NULL
10	NULL
15	NULL
24	NULL
CD2	NULL
CD2	NULL
+	NULL
ill	NULL
.	NULL

g	NULL
,	NULL
ech	NULL
``	NULL
#	NULL
#	NULL
FIGURE	NULL
2	NULL
.	NULL

Effect	NULL
of	NULL
costimulation	NULL
by	NULL
anti-CD28	NULL
on	NULL
IL-2	NULL
mRNA	NULL
accumulation	NULL
in	NULL
LPMC	NULL
and	NULL
LP-like	NULL
T	NULL
cells	NULL
activated	NULL
via	NULL
the	NULL
CD2	NULL
pathway	NULL
.	NULL

EtBr	NULL
represents	NULL
ethidium	NULL
bromide	NULL
staining	NULL
of	NULL
the	NULL
ribosomal	NULL
RNA	NULL
from	NULL
equalized	NULL
RNA	NULL
samples	NULL
used	NULL
to	NULL
prepare	NULL
the	NULL
Northern	NULL
blot	NULL
.	NULL

A	NULL
,	NULL
LPMC	NULL
from	NULL
inflamed	NULL
mucosa	NULL
stimulated	NULL
with	NULL
1	NULL
pg	NULL
anti-CD2/108	NULL
cells	NULL
or	NULL
1	NULL
ug	NULL
cells	NULL
+	NULL
1	NULL
ug	NULL
anti-CD28/10°	NULL
cells	NULL
.	NULL

B	NULL
,	NULL
PBL	NULL
cultured	NULL
5	NULL
days	NULL
in	NULL
IL-2	NULL
with	NULL
irradiated	NULL
Daudi	NULL
cells	NULL
(	NULL
LP-like	NULL
T	NULL
cells	NULL
)	NULL
prior	NULL
to	NULL
stimulation	NULL
with	NULL
anti-CD2	NULL
or	NULL
anti-CD2	NULL
+	NULL
anti-CD28	NULL
.	NULL

Representative	NULL
of	NULL
three	NULL
experiments	NULL
with	NULL
similar	NULL
results	NULL
is	NULL
shown	NULL
.	NULL

CD2	NULL
+	NULL
CD28	NULL
are	NULL
similar	NULL
to	NULL
those	NULL
seen	NULL
in	NULL
LPMC	NULL
from	NULL
inflamed	NULL
mucosa	NULL
.	NULL

Activation	NULL
of	NULL
LP-like	NULL
T	NULL
cells	NULL
via	NULL
the	NULL
CD2	NULL
pathway	NULL
resulted	NULL
in	NULL
a	NULL
steady	NULL
increase	NULL
in	NULL
IL-2	NULL
secretion	NULL
within	NULL
3	NULL
h.	NULL
The	NULL
increase	NULL
in	NULL
IL-2	NULL
persisted	NULL
throughout	NULL
24	NULL
h.	NULL
IL-2	NULL
mRNA	NULL
was	NULL
detectable	NULL
within	NULL
2	NULL
h	NULL
,	NULL
and	NULL
persisted	NULL
over	NULL
6	NULL
h	NULL
,	NULL
but	NULL
declined	NULL
by	NULL
10	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
IL-2	NULL
mRNA	NULL
expressed	NULL
in	NULL
LP-like	NULL
T	NULL
cells	NULL
costimulated	NULL
with	NULL
CD28	NULL
were	NULL
significantly	NULL
elevated	NULL
compared	NULL
with	NULL
those	NULL
stimulated	NULL
with	NULL
CD2	NULL
alone	NULL
.	NULL

Increased	NULL
IL-2	NULL
mRNA	NULL
expression	NULL
in	NULL
CD2-	NULL
and	NULL
CD28-costimulated	NULL
LP-like	NULL
T	NULL
cells	NULL
was	NULL
still	NULL
detectable	NULL
at	NULL
10	NULL
h	NULL
and	NULL
remained	NULL
elevated	NULL
at	NULL
the	NULL
24-h	NULL
time	NULL
point	NULL
.	NULL

CD28	NULL
alone	NULL
was	NULL
unable	NULL
to	NULL
induce	NULL
cytokine	NULL
production	NULL
or	NULL
expression	NULL
of	NULL
IL-2	NULL
mRNA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
CD28	NULL
costimulation	NULL
of	NULL
the	NULL
CD2	NULL
activation	NULL
pathway	NULL
leads	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
IL-2	NULL
secretion	NULL
that	NULL
is	NULL
paralleled	NULL
by	NULL
enhanced	NULL
level	NULL
and	NULL
duration	NULL
of	NULL
IL-2	NULL
mRNA	NULL
expression	NULL
in	NULL
both	NULL
LPMC	NULL
and	NULL
LP-like	NULL
T	NULL
cells	NULL
.	NULL

Costimulation	NULL
by	NULL
CD28	NULL
enhances	NULL
mRNA	NULL
stability	NULL
in	NULL
LPMC	NULL
and	NULL
LP-like	NULL
T	NULL
cell	NULL
activated	NULL
via	NULL
the	NULL
CD2	NULL
pathway	NULL
The	NULL
increased	NULL
IL-2	NULL
mRNA	NULL
accumulation	NULL
induced	NULL
by	NULL
CD2	NULL
and	NULL
CD28	NULL
coligation	NULL
could	NULL
be	NULL
related	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
mRNA	NULL
transcription	NULL
,	NULL
processing	NULL
,	NULL
and/or	NULL
enhanced	NULL
mRNA	NULL
stability	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
this	NULL
augmentation	NULL
was	NULL
related	NULL
to	NULL
mRNA	NULL
stability	NULL
,	NULL
LPMC	NULL
from	NULL
inflamed	NULL
mucosa	NULL
were	NULL
preactivated	NULL
by	NULL
CD2	NULL
or	NULL
CD2	NULL
and	NULL
CD28	NULL
for	NULL
2	NULL
h	NULL
(	NULL
maximum	NULL
for	NULL
mRNA	NULL
expression	NULL
in	NULL
LPMC	NULL
is	NULL
2-4	NULL
h	NULL
)	NULL
.	NULL

Actinomycin	NULL
D	NULL
was	NULL
added	NULL
to	NULL
prevent	NULL
further	NULL
transcription	NULL
,	NULL
and	NULL
mRNA	NULL
decay	NULL
was	NULL
monitored	NULL
for	NULL
the	NULL
time	NULL
periods	NULL
indicated	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
.	NULL

CD28	NULL
coligation	NULL
extended	NULL
the	NULL
/	NULL
of	NULL
IL-2	NULL
mRNA	NULL
from	NULL
70	NULL
to	NULL
180	NULL
min	NULL
.	NULL

A	NULL
strikingly	NULL
similar	NULL
result	NULL
was	NULL
obtained	NULL
with	NULL
LP-like	NULL
T	NULL
cells	NULL
.	NULL

LP-like	NULL
T	NULL
cells	NULL
were	NULL
preactivated	NULL
by	NULL
CD2	NULL
or	NULL
CD2	NULL
and	NULL
CD28	NULL
for	NULL
5	NULL
h	NULL
(	NULL
to	NULL
maximize	NULL
mRNA	NULL
expression	NULL
in	NULL
LP-like	NULL
T	NULL
cells	NULL
)	NULL
.	NULL

As	NULL
seen	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
the	NULL
:	NULL
s	NULL
of	NULL
IL-2	NULL
mRNA	NULL
from	NULL
CD2-activated	NULL
LP-like	NULL
T	NULL
cells	NULL
was	NULL
60	NULL
min	NULL
compared	NULL
with	NULL
over	NULL
200	NULL
min	NULL
following	NULL
CD28	NULL
costimulation	NULL
.	NULL

Thus	NULL
,	NULL
CD28	NULL
costimulation	NULL
increases	NULL
the	NULL
stability	NULL
of	NULL
IL-2	NULL
mRNA	NULL
in	NULL
both	NULL
LPMC	NULL
and	NULL
LP-like	NULL
T	NULL
cells	NULL
activated	NULL
via	NULL
the	NULL
CD2	NULL
pathway	NULL
.	NULL

CD28	NULL
costimulation	NULL
of	NULL
CD2-activated	NULL
LPMC	NULL
does	NULL
not	NULL
affect	NULL
the	NULL
transcriptional	NULL
rate	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
Previous	NULL
studies	NULL
carried	NULL
out	NULL
with	NULL
activated	NULL
PBMC	NULL
have	NULL
reported	NULL
increased	NULL
transcription	NULL
after	NULL
CD28	NULL
costimulation	NULL
of	NULL
the	NULL
CD3	NULL
pathway	NULL
(	NULL
26	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
contribution	NULL
of	NULL
CD28	NULL
signaling	NULL
on	NULL
initiation	NULL
of	NULL
IL-2	NULL
gene	NULL
transcription	NULL
in	NULL
LPMC	NULL
,	NULL
run-on	NULL
assays	NULL
were	NULL
performed	NULL
.	NULL

Nuclei	NULL
were	NULL
isolated	NULL
from	NULL
LPMC	NULL
activated	NULL
by	NULL
CD2	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
CD28	NULL
costimulation	NULL
.	NULL

As	NULL
seen	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
while	NULL
IL-2	NULL
gene	NULL
transcription	NULL
was	NULL
undetectable	NULL
in	NULL
unstimulated	NULL
LPMC	NULL
,	NULL
following	NULL
CD2	NULL
activation	NULL
induction	NULL
of	NULL
IL-2	NULL
transcription	NULL
was	NULL
evident	NULL
.	NULL

CD28	NULL
costimulation	NULL
,	NULL
however	NULL
,	NULL
did	NULL
not	NULL
result	NULL
in	NULL
an	NULL
increased	NULL
transcriptional	NULL
rate	NULL
above	NULL
that	NULL
observed	NULL
by	NULL
CD2	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Under	NULL
all	NULL
conditions	NULL
,	NULL
close	NULL
to	NULL
equivalent	NULL
levels	NULL
of	NULL
B-actin	NULL
were	NULL
detected	NULL
.	NULL

No	NULL
increase	NULL
in	NULL
signal	NULL
was	NULL
detected	NULL
hybridizing	NULL
to	NULL
the	NULL
plasmid	NULL
vector	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

To	NULL
further	NULL
study	NULL
transcriptional	NULL
activation	NULL
,	NULL
a	NULL
wild-type	NULL
IL-2	NULL
promoter	NULL
reporter	NULL
luciferase	NULL
construct	NULL
encompassing	NULL
the	NULL
CD28RE	NULL
,	NULL
known	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
CD28	NULL
enhanced	NULL
gene	NULL
transcription	NULL
in	NULL
PBMC	NULL
,	NULL
was	NULL
transfected	NULL
into	NULL
LPMC	NULL
activated	NULL
by	NULL
CD2	NULL
,	NULL
and	NULL
LPMC	NULL
activated	NULL
by	NULL
CD2	NULL
and	NULL
CD28	NULL
.	NULL

Fig	NULL
.	NULL

5	NULL
shows	NULL
that	NULL
in	NULL
contrast	NULL
to	NULL
results	NULL
in	NULL
PBMC	NULL
,	NULL
CD2	NULL
+	NULL
CD28	NULL
coligation	NULL
did	NULL
not	NULL
significantly	NULL
increase	NULL
IL-2	NULL
transcription	NULL
in	NULL
LPMC	NULL
from	NULL
normal	NULL
or	NULL
inflamed	NULL
mucosa	NULL
over	NULL
that	NULL
induced	NULL
by	NULL
CD2	NULL
alone	NULL
.	NULL

As	NULL
reported	NULL
recently	NULL
,	NULL
CD2	NULL
signaling	NULL
in	NULL
LPMC	NULL
is	NULL
transmitted	NULL
in	NULL
part	NULL
by	NULL
induction	NULL
of	NULL
AP-1-transactivating	NULL
factors	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

6	NULL
demonstrates	NULL
that	NULL
while	NULL
CD2	NULL
ligation	NULL
results	NULL
in	NULL
transactivation	NULL
of	NULL
a	NULL
multimeric	NULL
AP-1-binding	NULL
TREZ	NULL
reporter	NULL
construct	NULL
in	NULL
LPMC	NULL
from	NULL
normal	NULL
or	NULL
inflamed	NULL
mucosa	NULL
,	NULL
coligation	NULL
of	NULL
CD28	NULL
was	NULL
unable	NULL
to	NULL
further	NULL
enhance	NULL
promoter	NULL
activity	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
while	NULL
there	NULL
is	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
6625	NULL
A	NULL
min	NULL
.	NULL

125	NULL
after	NULL
Act	NULL
D	NULL
0	NULL
40	NULL
80	NULL
120	NULL
160	NULL
200	NULL
EtBr	NULL
-E-	NULL
CD2	NULL
>	NULL
)	NULL
-e-	NULL
CD2	NULL
+	NULL
.	NULL

#	NULL
=	NULL
10	NULL
CD28	NULL
€	NULL
cb2	NULL
5	NULL
75	NULL
)	NULL
<	NULL
f	NULL
$	NULL
5	NULL
@	NULL
ta	NULL
-	NULL
u	NULL
[	NULL
2a	NULL
&	NULL
e	NULL
E	NULL
€	NULL
25	NULL
)	NULL
F	NULL
a	NULL
CD2	NULL
+	NULL
CD28	NULL
°o	NULL
50	NULL
100	NULL
150	NULL
200	NULL
Time	NULL
(	NULL
min	NULL
after	NULL
Act	NULL
.	NULL

D	NULL
)	NULL
B	NULL
min	NULL
after	NULL
ActD	NULL
_	NULL
O0	NULL
-	NULL
40	NULL
80	NULL
120	NULL
160	NULL
200	NULL
EtBr	NULL
-B-	NULL
CD2	NULL
125	NULL
|	NULL
|	NULL
_	NULL
&	NULL
-cp2cp2s	NULL
K	NULL
100	NULL
CD2	NULL
o	NULL
O	NULL
CO8	NULL
ee	NULL
%	NULL
mRNA	NULL
remaining	NULL
N	NULL
on	NULL
5	NULL
}	NULL
)	NULL
(	NULL
0	NULL
50	NULL
100	NULL
150	NULL
200	NULL
Time	NULL
(	NULL
min	NULL
after	NULL
Act	NULL
.	NULL

D	NULL
)	NULL
CD2	NULL
+	NULL
CD28	NULL
FIGURE	NULL
3	NULL
.	NULL

Half-life	NULL
of	NULL
IL-2	NULL
mRNA	NULL
following	NULL
anti-CD2	NULL
activation	NULL
.	NULL

LPMC	NULL
from	NULL
inflamed	NULL
mucosa	NULL
(	NULL
A	NULL
)	NULL
or	NULL
LP-like	NULL
T	NULL
cells	NULL
(	NULL
B	NULL
)	NULL
were	NULL
preactivated	NULL
by	NULL
1	NULL
ug	NULL
anti-CD2/108	NULL
cells	NULL
or	NULL
1	NULL
ug	NULL
anti-CD2/10°	NULL
cells	NULL
+	NULL
1	NULL
ug	NULL
anti-CD28/10°	NULL
cells	NULL
for	NULL
2	NULL
h	NULL
or	NULL
5	NULL
h	NULL
,	NULL
respectively	NULL
,	NULL
followed	NULL
by	NULL
addition	NULL
of	NULL
actinomycin	NULL
D	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
to	NULL
prevent	NULL
further	NULL
transcription	NULL
.	NULL

Northern	NULL
blots	NULL
were	NULL
prepared	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
mRNA	NULL
was	NULL
determined	NULL
at	NULL
indicated	NULL
time	NULL
points	NULL
by	NULL
scanning	NULL
densitometry	NULL
(	NULL
left	NULL
panel	NULL
)	NULL
.	NULL

EtBt	NULL
represents	NULL
ethidium	NULL
bromide	NULL
staining	NULL
of	NULL
the	NULL
ribosomal	NULL
RNA	NULL
from	NULL
equalized	NULL
RNA	NULL
samples	NULL
used	NULL
to	NULL
prepare	NULL
the	NULL
Northern	NULL
blot	NULL
.	NULL

Repre-	NULL
sentative	NULL
of	NULL
three	NULL
experiments	NULL
with	NULL
similar	NULL
results	NULL
is	NULL
shown	NULL
.	NULL

an	NULL
increase	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
activity	NULL
following	NULL
CD2	NULL
pathway	NULL
activation	NULL
of	NULL
LPMC	NULL
,	NULL
costimulation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CD28	NULL
does	NULL
not	NULL
further	NULL
increase	NULL
transcriptional	NULL
activity	NULL
.	NULL

Activation	NULL
of	NULL
LPMC	NULL
via	NULL
the	NULL
CD28	NULL
pathway	NULL
does	NULL
not	NULL
enhance	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
to	NULL
the	NULL
CD28RE	NULL
,	NULL
or	NULL
decrease	NULL
I-	NULL
«	NULL
kB	NULL
function	NULL
in	NULL
LPMC	NULL
and	NULL
LP-like	NULL
T	NULL
cells	NULL
Previous	NULL
studies	NULL
have	NULL
identified	NULL
a	NULL
CD28RE	NULL
within	NULL
the	NULL
IL-2	NULL
promoter	NULL
region	NULL
that	NULL
is	NULL
required	NULL
for	NULL
transcriptional	NULL
induction	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
by	NULL
CD28	NULL
costimulated	NULL
PBMC	NULL
and	NULL
T	NULL
cell	NULL
lines	NULL
(	NULL
8	NULL
,	NULL
9	NULL
,	NULL
26	NULL
)	NULL
.	NULL

It	NULL
is	NULL
believed	NULL
that	NULL
the	NULL
complexes	NULL
binding	NULL
to	NULL
the	NULL
CD28RE	NULL
are	NULL
members	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B/Re	NULL
!	NULL

family	NULL
,	NULL
the	NULL
function	NULL
of	NULL
which	NULL
is	NULL
regulated	NULL
by	NULL
sequestration	NULL
of	NULL
binding	NULL
of	NULL
inhibitory	NULL
I-	NULL
«	NULL
B	NULL
proteins	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

The	NULL
results	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
suggest	NULL
that	NULL
while	NULL
the	NULL
IL-2	NULL
promoter	NULL
containing	NULL
the	NULL
CD28RE	NULL
responds	NULL
to	NULL
CD2	NULL
activation	NULL
,	NULL
the	NULL
CD28RE	NULL
is	NULL
not	NULL
the	NULL
site	NULL
at	NULL
which	NULL
transactivation	NULL
is	NULL
enhanced	NULL
following	NULL
CD28	NULL
coligation	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
effect	NULL
of	NULL
CD28	NULL
coligation	NULL
on	NULL
functional	NULL
regulation	NULL
of	NULL
the	NULL
CD28RE	NULL
in	NULL
our	NULL
system	NULL
,	NULL
LP-like	NULL
T	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
CD2	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
CD28	NULL
costimulation	NULL
and	NULL
nuclear	NULL
proteins	NULL
were	NULL
analyzed	NULL
for	NULL
binding	NULL
to	NULL
the	NULL
composite	NULL
CD28RE/AP-1	NULL
cis	NULL
regulatory	NULL
element	NULL
by	NULL
EMSA	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
a	NULL
very	NULL
modest	NULL
increase	NULL
in	NULL
binding	NULL
of	NULL
complexes	NULL
to	NULL
the	NULL
CD28RE/AP-1	NULL
element	NULL
was	NULL
detected	NULL
following	NULL
CD2	NULL
activation	NULL
.	NULL

No	NULL
additional	NULL
alteration	NULL
in	NULL
the	NULL
binding	NULL
of	NULL
this	NULL
complex	NULL
was	NULL
detectable	NULL
following	NULL
CD28	NULL
costimulation	NULL
.	NULL

Furthermore	NULL
,	NULL
Western	NULL
A	NULL
Untreated	NULL
CD2	NULL
CD2	NULL
+	NULL
CD28	NULL
It	NULL
~~	NULL
#	NULL
»	NULL
m	NULL
_	NULL
ff	NULL
<	NULL
p	NULL
&	NULL
Actin	NULL
-	NULL
>	NULL
|	NULL
@	NULL
@	NULL
(	NULL
g	NULL
-	NULL
>	NULL
soe	NULL
0	NULL
-	NULL
atas	NULL
B	NULL
500	NULL
7	NULL
2	NULL
#	NULL
s	NULL
mud	NULL
a	NULL
:	NULL
2300	NULL
|-	NULL
$	NULL
2	NULL
©	NULL
|	NULL
6	NULL
E	NULL
=	NULL
f	NULL
untreate	NULL
o	NULL
2200	NULL
treated	NULL
CD2	NULL
CD2+28	NULL
7	NULL
5100	NULL
o	NULL
0	NULL
CD2	NULL
CD2	NULL
+	NULL
CD28	NULL
FIGURE	NULL
4	NULL
.	NULL

Nuclear	NULL
run-on	NULL
analysis	NULL
of	NULL
IL-2	NULL
mRNA	NULL
.	NULL

LPMC	NULL
were	NULL
preactivated	NULL
by	NULL
1	NULL
ug	NULL
anti-CD2/10®	NULL
cells	NULL
or	NULL
1	NULL
ug	NULL
anti-CD2/10®	NULL
cells	NULL
+	NULL
1	NULL
ug	NULL
anti-CD28/10°	NULL
cells	NULL
for	NULL
2	NULL
h	NULL
and	NULL
nuclei	NULL
were	NULL
isolated	NULL
.	NULL

A	NULL
,	NULL
Run-on	NULL
assays	NULL
were	NULL
performed	NULL
and	NULL
transcripts	NULL
were	NULL
hybridized	NULL
to	NULL
filter	NULL
containing	NULL
2	NULL
ug	NULL
of	NULL
plasmid	NULL
inserts	NULL
specific	NULL
for	NULL
human	NULL
IL-2	NULL
or	NULL
B-actin	NULL
.	NULL

B	NULL
,	NULL
Densitometric	NULL
readings	NULL
of	NULL
run-on	NULL
in	NULL
A.	NULL
Densitometric	NULL
units	NULL
were	NULL
calculated	NULL
from	NULL
B-actin	NULL
and	NULL
used	NULL
to	NULL
correct	NULL
the	NULL
readings	NULL
for	NULL
IL-2	NULL
mRNA	NULL
and	NULL
empty	NULL
vector	NULL
.	NULL

Representative	NULL
of	NULL
two	NULL
experiments	NULL
with	NULL
similar	NULL
results	NULL
is	NULL
shown	NULL
.	NULL

Untreated	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
6626	NULL
80	NULL
&	NULL
D	NULL
O	NULL
Fold	NULL
Increase	NULL
J	NULL
O	NULL
20	NULL
}	NULL
0	NULL
P	NULL
&	NULL
$	NULL
0K0	NULL
QQ	NULL
6°	NULL
?	NULL

«	NULL
5	NULL
«	NULL
°	NULL
o	NULL
g	NULL
S	NULL
FIGURE	NULL
5	NULL
.	NULL

Transfection	NULL
of	NULL
LPMC	NULL
with	NULL
an	NULL
IL-2	NULL
promoter-luciferase	NULL
sequence	NULL
.	NULL

Freshly	NULL
isolated	NULL
LPMC	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
pg/ml	NULL
PHA-L	NULL
for	NULL
20	NULL
h	NULL
and	NULL
electroporated	NULL
with	NULL
the	NULL
IL-2	NULL
promoter	NULL
construct	NULL
.	NULL

Electroporated	NULL
cells	NULL
were	NULL
rested	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
either	NULL
20	NULL
g/ml	NULL
PMA	NULL
plus	NULL
400	NULL
nM	NULL
calcium	NULL
ionophore	NULL
,	NULL
1	NULL
ug	NULL
cells	NULL
plus	NULL
or	NULL
minus	NULL
1	NULL
ug	NULL
anti-CD28/10°	NULL
cells	NULL
for	NULL
4	NULL
h.	NULL
Luminescence	NULL
was	NULL
measured	NULL
using	NULL
a	NULL
Promega	NULL
luciferase	NULL
assay	NULL
kit	NULL
,	NULL
counted	NULL
on	NULL
a	NULL
six	NULL
detector	NULL
Wallac	NULL
1450	NULL
Microbeta	NULL
liquid	NULL
scintillation	NULL
counter	NULL
(	NULL
Wallac	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
with	NULL
coincidence	NULL
counting	NULL
turned	NULL
off	NULL
.	NULL

Fold	NULL
increase	NULL
was	NULL
calculated	NULL
as	NULL
the	NULL
ratio	NULL
of	NULL
cpm	NULL
stimulated	NULL
divided	NULL
by	NULL
cpm	NULL
unstimulated	NULL
.	NULL

Unstimulated	NULL
cpm	NULL
was	NULL
41	NULL
.	NULL

Representative	NULL
of	NULL
four	NULL
experiments	NULL
with	NULL
similar	NULL
results	NULL
is	NULL
shown	NULL
.	NULL

blot	NULL
analysis	NULL
revealed	NULL
that	NULL
CD2	NULL
activation	NULL
precipitated	NULL
a	NULL
striking	NULL
loss	NULL
of	NULL
IxBa	NULL
within	NULL
2	NULL
h	NULL
,	NULL
which	NULL
was	NULL
then	NULL
rapidly	NULL
restored	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
decrease	NULL
from	NULL
baseline	NULL
of	NULL
I-kBa	NULL
was	NULL
generated	NULL
by	NULL
CD28	NULL
costimulation	NULL
.	NULL

IxBB	NULL
proteins	NULL
were	NULL
not	NULL
significantly	NULL
altered	NULL
following	NULL
CD2	NULL
activation	NULL
whether	NULL
or	NULL
not	NULL
CD28	NULL
was	NULL
present	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
)	NULL
.	NULL

This	NULL
data	NULL
are	NULL
consistent	NULL
with	NULL
transfection	NULL
functional	NULL
analysis	NULL
and	NULL
the	NULL
EMSA	NULL
data	NULL
,	NULL
suggesting	NULL
that	NULL
CD28	NULL
costimulation	NULL
does	NULL
not	NULL
result	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
either	NULL
binding	NULL
of	NULL
trans-acting	NULL
factors	NULL
to	NULL
the	NULL
CD28RE	NULL
promoter	NULL
region	NULL
or	NULL
increased	NULL
promoter	NULL
activation	NULL
over	NULL
that	NULL
induced	NULL
by	NULL
CD2	NULL
alone	NULL
.	NULL

160	NULL
'	NULL
Fold	NULL
Increase	NULL
N	NULL
Go	NULL
O	NULL
[	NULL
=	NULL
O	NULL
0	NULL
Unstim	NULL
.	NULL

CD2	NULL
CD2	NULL
+	NULL
CD28	NULL
CD28	NULL
-	NULL
PMA¥/Iion	NULL
FIGURE	NULL
6	NULL
.	NULL

Transfection	NULL
of	NULL
LPMC	NULL
with	NULL
an	NULL
IL-2	NULL
TRE2	NULL
promoter-luciferase	NULL
sequence	NULL
.	NULL

Freshly	NULL
isolated	NULL
LPMC	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
ug/ml	NULL
PHA-L	NULL
for	NULL
20	NULL
h	NULL
and	NULL
electroporated	NULL
with	NULL
the	NULL
TREZ	NULL
promoter	NULL
construct	NULL
.	NULL

Electroporated	NULL
cells	NULL
were	NULL
rested	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
1	NULL
ug	NULL
anti-CD2/10°	NULL
cells	NULL
plus	NULL
or	NULL
minus	NULL
1	NULL
ug	NULL
anti-CD28/10°	NULL
cells	NULL
for	NULL
4	NULL
h.	NULL
Luminescence	NULL
was	NULL
measured	NULL
using	NULL
a	NULL
Promega	NULL
luciferase	NULL
assay	NULL
kit	NULL
,	NULL
counted	NULL
on	NULL
a	NULL
six	NULL
detector	NULL
Wallac	NULL
1450	NULL
Microbeta	NULL
liquid	NULL
scintillation	NULL
counter	NULL
with	NULL
coincidence	NULL
counting	NULL
turned	NULL
off	NULL
.	NULL

Fold	NULL
increase	NULL
was	NULL
calculated	NULL
as	NULL
the	NULL
ratio	NULL
of	NULL
cpm	NULL
stimulated	NULL
divided	NULL
by	NULL
cpm	NULL
unstimulated	NULL
.	NULL

Mean	NULL
unstimulated	NULL
cpm	NULL
was	NULL
380,000	NULL
.	NULL

Means	NULL
(	NULL
+SEM	NULL
)	NULL
of	NULL
three	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

TRANSACTIVATION	NULL
OF	NULL
THE	NULL
IL-2	NULL
PROMOTER	NULL
(	NULL
min	NULL
)	NULL
0	NULL
15	NULL
30	NULL
60	NULL
120	NULL
_C	NULL
NS	NULL
Cp2	NULL
8	NULL
``	NULL
w	NULL
a	NULL
»	NULL
#	NULL
ag	NULL
CD2	NULL
+	NULL
CD2s	NULL
w	NULL
2	NULL
ID	NULL
®	NULL
FIGURE	NULL
7	NULL
.	NULL

EMSA	NULL
analysis	NULL
of	NULL
5	NULL
pug	NULL
nuclear	NULL
protein	NULL
isolated	NULL
from	NULL
LPMC	NULL
binding	NULL
to	NULL
the	NULL
CD28RE/AP-1	NULL
element	NULL
following	NULL
stimulation	NULL
with	NULL
by	NULL
1	NULL
ug	NULL
anti-CD2/10°	NULL
cells	NULL
or	NULL
1	NULL
pg	NULL
cells	NULL
+	NULL
1	NULL
ug	NULL
anti-CD28/	NULL
10°	NULL
cells	NULL
.	NULL

Lanes	NULL
:	NULL
C	NULL
,	NULL
competition	NULL
with	NULL
100-fold	NULL
excess	NULL
CD28RE	NULL
oligo	NULL
;	NULL
NS	NULL
,	NULL
competition	NULL
with	NULL
100-fold	NULL
excess	NULL
nonspecific	NULL
oligonucleotide	NULL
.	NULL

Representative	NULL
of	NULL
three	NULL
experiments	NULL
with	NULL
similar	NULL
results	NULL
is	NULL
shown	NULL
.	NULL

Activation	NULL
of	NULL
LPMC	NULL
via	NULL
the	NULL
CD28	NULL
pathway	NULL
does	NULL
not	NULL
significantly	NULL
enhance	NULL
transcriptional	NULL
expression	NULL
of	NULL
composite	NULL
CD28/AP	NULL
promoter-reporter	NULL
construct	NULL
Previous	NULL
studies	NULL
carried	NULL
out	NULL
in	NULL
T	NULL
cell	NULL
lines	NULL
have	NULL
demonstrated	NULL
that	NULL
transactivation	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
following	NULL
CD28	NULL
coligation	NULL
is	NULL
conferred	NULL
through	NULL
a	NULL
composite	NULL
element	NULL
,	NULL
RE/AP	NULL
,	NULL
consisting	NULL
of	NULL
the	NULL
synergistic	NULL
interaction	NULL
of	NULL
both	NULL
the	NULL
CD28RE	NULL
and	NULL
the	NULL
adjacent	NULL
nonconsensus	NULL
AP-1-binding	NULL
site	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
either	NULL
one	NULL
of	NULL
these	NULL
components	NULL
was	NULL
sufficient	NULL
for	NULL
abolishing	NULL
the	NULL
CD28	NULL
response	NULL
of	NULL
RE/AP	NULL
promoter-reporter	NULL
constructs	NULL
transfected	NULL
into	NULL
T	NULL
cell	NULL
lines	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
above	NULL
supported	NULL
the	NULL
hypothesis	NULL
that	NULL
following	NULL
CD28	NULL
costimulation	NULL
of	NULL
LPMC	NULL
no	NULL
transcriptional	NULL
up-regulation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
could	NULL
be	NULL
detected	NULL
over	NULL
that	NULL
observed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CD2	NULL
alone	NULL
.	NULL

However	NULL
,	NULL
most	NULL
of	NULL
the	NULL
information	NULL
regarding	NULL
our	NULL
understanding	NULL
of	NULL
transcriptional	NULL
regulation	NULL
of	NULL
IL-2	NULL
expression	NULL
has	NULL
been	NULL
performed	NULL
in	NULL
T	NULL
cell	NULL
line	NULL
systems	NULL
rather	NULL
than	NULL
primary	NULL
T	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
seemed	NULL
possible	NULL
that	NULL
the	NULL
failure	NULL
to	NULL
detect	NULL
transcriptional	NULL
up-regulation	NULL
following	NULL
CD28	NULL
coactivation	NULL
of	NULL
LPMC	NULL
might	NULL
not	NULL
be	NULL
unique	NULL
for	NULL
mucosal	NULL
T	NULL
cells	NULL
but	NULL
,	NULL
rather	NULL
,	NULL
might	NULL
be	NULL
due	NULL
to	NULL
unique	NULL
transcriptional	NULL
regulatory	NULL
mechanisms	NULL
related	NULL
to	NULL
primary	NULL
T	NULL
cells	NULL
compared	NULL
with	NULL
T	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
order	NULL
to	NULL
investigate	NULL
this	NULL
possibility	NULL
,	NULL
PBMC	NULL
were	NULL
transfected	NULL
with	NULL
multim-erized	NULL
RE/AP	NULL
and	NULL
mutant	NULL
RE/AP	NULL
reporter	NULL
constructs	NULL
,	NULL
and	NULL
expression	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
LPMC	NULL
following	NULL
CD2	NULL
and	NULL
CD2	NULL
+	NULL
CD28	NULL
costimulation	NULL
.	NULL

Fig	NULL
.	NULL

9	NULL
shows	NULL
that	NULL
there	NULL
is	NULL
approximately	NULL
a	NULL
10-fold	NULL
activation	NULL
of	NULL
the	NULL
composite	NULL
RE/AP	NULL
construct	NULL
in	NULL
response	NULL
to	NULL
CD2	NULL
stimulation	NULL
in	NULL
both	NULL
peripheral	NULL
T	NULL
cells	NULL
and	NULL
LPMC	NULL
.	NULL

Moreover	NULL
,	NULL
A	NULL
(	NULL
hours	NULL
)	NULL
0	NULL
é	NULL
1	NULL
CD2	NULL
«	NULL
wees	NULL
-	NULL
uae	NULL
IxBa	NULL
.	NULL

2	NULL
6	NULL
10	NULL
1s	NULL
24	NULL
CD2	NULL
+	NULL
CD28	NULL
``	NULL
Whi	NULL
came	NULL
«	NULL
mmo	NULL
:	NULL
cmm	NULL
.	NULL

ames	NULL
B	NULL
IBB	NULL
(	NULL
hours	NULL
)	NULL
0	NULL
%	NULL
15	NULL
1	NULL
2	NULL
3	NULL
6	NULL
24	NULL
CD2	NULL
**	NULL
_	NULL
sas	NULL
it	NULL
T	NULL
Tt	NULL
~~	NULL
.	NULL

giz	NULL
Tn	NULL
CD2	NULL
+	NULL
CD28	NULL
we	NULL
ap	NULL
.	NULL

fie	NULL
-	NULL
<	NULL
7	NULL
``	NULL
-	NULL
armouy	NULL
-	NULL
aug	NULL
-	NULL
``	NULL
``	NULL
FIGURE	NULL
8	NULL
.	NULL

-	NULL
Kinetics	NULL
of	NULL
IxBa	NULL
(	NULL
A	NULL
)	NULL
and	NULL
IBB	NULL
(	NULL
B	NULL
)	NULL
binding	NULL
following	NULL
CD2	NULL
activation	NULL
.	NULL

PBL	NULL
were	NULL
cultured	NULL
5	NULL
days	NULL
in	NULL
IL-2	NULL
with	NULL
irradiated	NULL
Daudi	NULL
cells	NULL
(	NULL
LP-like	NULL
T	NULL
cells	NULL
)	NULL
and	NULL
stimulated	NULL
with	NULL
anti-CD2	NULL
or	NULL
anti-CD2	NULL
+	NULL
anti-CD28	NULL
.	NULL

Western	NULL
blot	NULL
was	NULL
used	NULL
to	NULL
determine	NULL
the	NULL
presence	NULL
of	NULL
IxBa	NULL
and	NULL
I	NULL
«	NULL
BB	NULL
nuclear	NULL
proteins	NULL
.	NULL

Representative	NULL
of	NULL
three	NULL
experiments	NULL
with	NULL
similar	NULL
results	NULL
is	NULL
shown	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
A	NULL
B	NULL
LPMC	NULL
PBMC	NULL
1000	NULL
1000	NULL
;	NULL
[	NULL
_	NULL
]	NULL
cp	NULL
100	NULL
L_	NULL
]	NULL
coz	NULL
100	NULL
WW	NULL
co2+	NULL
002	NULL
EW	NULL
co2	NULL
+	NULL
cor	NULL
10	NULL
10	NULL
Fold	NULL
Increase	NULL
RE/AP	NULL
-	NULL
REm/AP	NULL
RE/APmREm/APm	NULL
RE/AP	NULL
-	NULL
REm/AP	NULL
RE/APmREm/APm	NULL
FIGURE	NULL
9	NULL
.	NULL

Transfection	NULL
of	NULL
LPMC	NULL
and	NULL
PBMC	NULL
with	NULL
human	NULL
IL-2	NULL
promoter-reporter	NULL
constructs	NULL
.	NULL

Freshly	NULL
isolated	NULL
LPMC	NULL
and	NULL
PBMC	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
ug/ml	NULL
PHA-L	NULL
for	NULL
16	NULL
or	NULL
20	NULL
h	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
electroporated	NULL
with	NULL
the	NULL
RE/AP	NULL
and	NULL
mutant	NULL
RE/AP	NULL
promoter	NULL
constructs	NULL
.	NULL

Electroporated	NULL
cells	NULL
were	NULL
rested	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
1	NULL
g/ml	NULL
anti-CD2/10°	NULL
cells	NULL
plus	NULL
or	NULL
minus	NULL
1	NULL
pg/ml	NULL
anti-CD28/10°	NULL
cells	NULL
for	NULL
4	NULL
h.	NULL
Luminescence	NULL
was	NULL
measured	NULL
using	NULL
a	NULL
Promega	NULL
luciferase	NULL
assay	NULL
kit	NULL
,	NULL
counted	NULL
on	NULL
a	NULL
six	NULL
detector	NULL
Wallac	NULL
1450	NULL
Microbeta	NULL
liquid	NULL
scintillation	NULL
counter	NULL
with	NULL
coincidence	NULL
counting	NULL
turned	NULL
off	NULL
.	NULL

Fold	NULL
increase	NULL
was	NULL
calculated	NULL
as	NULL
the	NULL
ratio	NULL
of	NULL
cpm	NULL
stimulated	NULL
divided	NULL
by	NULL
cpm	NULL
unstimulated	NULL
.	NULL

Unstimulated	NULL
cpm	NULL
was	NULL
256	NULL
for	NULL
LPMC	NULL
and	NULL
116	NULL
for	NULL
PBMC	NULL
.	NULL

C	NULL
,	NULL
Anti-CD2	NULL
alone	NULL
;	NULL
M	NULL
,	NULL
anti-CD2	NULL
+	NULL
anti-CD28	NULL
.	NULL

Representative	NULL
of	NULL
five	NULL
experiments	NULL
with	NULL
similar	NULL
results	NULL
is	NULL
shown	NULL
.	NULL

similar	NULL
to	NULL
up-regulation	NULL
of	NULL
the	NULL
RE/AP	NULL
element	NULL
described	NULL
for	NULL
T	NULL
cell	NULL
lines	NULL
,	NULL
in	NULL
peripheral	NULL
T	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
RE/AP	NULL
reporter	NULL
construct	NULL
following	NULL
CD28	NULL
costimulation	NULL
,	NULL
there	NULL
is	NULL
enhanced	NULL
promoter	NULL
transactivation	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
from	NULL
14-	NULL
to	NULL
300-fold	NULL
)	NULL
;	NULL
however	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
peripheral	NULL
T	NULL
cells	NULL
,	NULL
in	NULL
LPMC	NULL
from	NULL
normal	NULL
mucosa	NULL
following	NULL
CD2	NULL
+	NULL
CD28	NULL
coligation	NULL
,	NULL
only	NULL
a	NULL
marginal	NULL
2-fold	NULL
increase	NULL
in	NULL
RE/AP	NULL
reporter	NULL
activation	NULL
was	NULL
noted	NULL
over	NULL
that	NULL
induced	NULL
by	NULL
CD2	NULL
alone	NULL
.	NULL

CD28	NULL
stimulation	NULL
alone	NULL
did	NULL
not	NULL
activate	NULL
promoter-reporter	NULL
constructs	NULL
in	NULL
all	NULL
cells	NULL
tested	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
mutation	NULL
of	NULL
either	NULL
the	NULL
CD28RE	NULL
or	NULL
adjacent	NULL
nonconsensus	NULL
AP-1	NULL
site	NULL
abolished	NULL
CD2	NULL
responsiveness	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
regulatory	NULL
mechanisms	NULL
involved	NULL
in	NULL
IL-2	NULL
gene	NULL
expression	NULL
following	NULL
CD28	NULL
pathway	NULL
stimulation	NULL
in	NULL
LPMC	NULL
are	NULL
distinct	NULL
from	NULL
those	NULL
observed	NULL
in	NULL
peripheral	NULL
T	NULL
cell	NULL
and	NULL
T	NULL
cell	NULL
lines	NULL
.	NULL

Discussion	NULL
In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
examined	NULL
molecular	NULL
events	NULL
and	NULL
mechanisms	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
IL-2	NULL
production	NULL
in	NULL
CD2-activated	NULL
LPMC	NULL
and	NULL
LP-like	NULL
T	NULL
cells	NULL
costimulated	NULL
with	NULL
CD28	NULL
.	NULL

IL-2	NULL
gene	NULL
expression	NULL
in	NULL
LPMC	NULL
and	NULL
LP-like	NULL
T	NULL
cells	NULL
is	NULL
highly	NULL
sensitive	NULL
to	NULL
CD2	NULL
activation	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Coligation	NULL
of	NULL
the	NULL
CD28	NULL
molecule	NULL
leads	NULL
to	NULL
a	NULL
synergistic	NULL
effect	NULL
,	NULL
further	NULL
enhancing	NULL
IL-2	NULL
secretion	NULL
in	NULL
these	NULL
cell	NULL
populations	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Our	NULL
data	NULL
show	NULL
that	NULL
,	NULL
in	NULL
LPMC	NULL
and	NULL
LP-like	NULL
T	NULL
cells	NULL
,	NULL
CD28	NULL
costimulation	NULL
enhanced	NULL
mRNA	NULL
stability	NULL
,	NULL
but	NULL
did	NULL
not	NULL
increase	NULL
the	NULL
rate	NULL
of	NULL
transcriptional	NULL
activation	NULL
.	NULL

Nuclear	NULL
run-on	NULL
data	NULL
as	NULL
well	NULL
as	NULL
transfection	NULL
of	NULL
a	NULL
600-bp	NULL
IL-2	NULL
promoter-reporter	NULL
construct	NULL
into	NULL
LPMC	NULL
revealed	NULL
significant	NULL
promoter	NULL
activity	NULL
following	NULL
CD2	NULL
activation	NULL
,	NULL
but	NULL
failed	NULL
to	NULL
exhibit	NULL
augmented	NULL
transcriptional	NULL
activation	NULL
following	NULL
CD2	NULL
+	NULL
CD28	NULL
costimulation	NULL
above	NULL
that	NULL
observed	NULL
with	NULL
CD2	NULL
alone	NULL
.	NULL

Likewise	NULL
,	NULL
expression	NULL
of	NULL
the	NULL
IL-2	NULL
RE/AP	NULL
composite	NULL
element	NULL
was	NULL
responsive	NULL
to	NULL
CD2	NULL
stimulation	NULL
but	NULL
failed	NULL
to	NULL
exhibit	NULL
enhanced	NULL
activity	NULL
following	NULL
CD28	NULL
costimulation	NULL
.	NULL

EMSA	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
the	NULL
CD28RE	NULL
cis	NULL
and	NULL
trans-acting	NULL
elements	NULL
support	NULL
the	NULL
conclusion	NULL
that	NULL
CD2	NULL
signaling	NULL
in	NULL
LPMC	NULL
leads	NULL
to	NULL
up-regulation	NULL
of	NULL
NF-	NULL
«	NULL
B-like	NULL
factors	NULL
paralleled	NULL
by	NULL
rapid	NULL
decrease	NULL
of	NULL
IxkBa	NULL
.	NULL

Costimulation	NULL
with	NULL
CD28	NULL
does	NULL
not	NULL
alter	NULL
this	NULL
pattern	NULL
of	NULL
expression	NULL
.	NULL

These	NULL
results	NULL
highlight	NULL
again	NULL
the	NULL
utility	NULL
of	NULL
6627	NULL
the	NULL
LP-like	NULL
T	NULL
cell	NULL
model	NULL
as	NULL
a	NULL
system	NULL
with	NULL
analogous	NULL
activation	NULL
properties	NULL
to	NULL
those	NULL
expressed	NULL
by	NULL
LPMC	NULL
,	NULL
which	NULL
allows	NULL
investigations	NULL
of	NULL
mucosal	NULL
cytokine	NULL
gene	NULL
regulation	NULL
to	NULL
be	NULL
performed	NULL
initially	NULL
on	NULL
a	NULL
more	NULL
easily	NULL
manipulated	NULL
experimental	NULL
system	NULL
.	NULL

Numerous	NULL
studies	NULL
have	NULL
been	NULL
carried	NULL
out	NULL
in	NULL
PBMC	NULL
and	NULL
tumor	NULL
T	NULL
cell	NULL
lines	NULL
activated	NULL
through	NULL
the	NULL
TCR	NULL
and	NULL
CD28	NULL
costimulation	NULL
,	NULL
which	NULL
indicated	NULL
that	NULL
CD28	NULL
synergism	NULL
was	NULL
due	NULL
to	NULL
both	NULL
increased	NULL
IL-2	NULL
mRNA	NULL
transcription	NULL
as	NULL
well	NULL
as	NULL
enhanced	NULL
mRNA	NULL
stability	NULL
(	NULL
8	NULL
,	NULL
13	NULL
,	NULL
27	NULL
,	NULL
28	NULL
)	NULL
.	NULL

CTLA-4	NULL
expression	NULL
is	NULL
likewise	NULL
enhanced	NULL
in	NULL
a	NULL
synergistic	NULL
fashion	NULL
following	NULL
TCR	NULL
and	NULL
CD28	NULL
costimulation	NULL
involving	NULL
a	NULL
mechanism	NULL
contributed	NULL
by	NULL
both	NULL
transcriptional	NULL
and	NULL
posttranscriptional	NULL
components	NULL
(	NULL
29	NULL
)	NULL
.	NULL

However	NULL
,	NULL
studies	NULL
performed	NULL
with	NULL
murine	NULL
T	NULL
cell	NULL
clones	NULL
suggest	NULL
that	NULL
in	NULL
these	NULL
cells	NULL
increased	NULL
IL-2	NULL
mRNA	NULL
production	NULL
is	NULL
mediated	NULL
by	NULL
a	NULL
more	NULL
complex	NULL
series	NULL
of	NULL
events	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Regulation	NULL
on	NULL
a	NULL
nuclear	NULL
level	NULL
does	NULL
not	NULL
involve	NULL
modification	NULL
of	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
,	NULL
but	NULL
rather	NULL
is	NULL
the	NULL
result	NULL
of	NULL
increased	NULL
expression	NULL
of	NULL
unspliced	NULL
IL-2	NULL
pre-mRNA	NULL
(	NULL
30	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
mechanism	NULL
of	NULL
posttranscriptional	NULL
regulation	NULL
of	NULL
IL-2	NULL
expression	NULL
,	NULL
at	NULL
the	NULL
level	NULL
of	NULL
pre-mRNA	NULL
splicing	NULL
and	NULL
processing	NULL
,	NULL
has	NULL
been	NULL
reported	NULL
in	NULL
PBMC	NULL
activated	NULL
with	NULL
PHA	NULL
but	NULL
without	NULL
CD28	NULL
costimulation	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
remains	NULL
uncertain	NULL
as	NULL
to	NULL
whether	NULL
the	NULL
nuclear	NULL
effects	NULL
of	NULL
CD28	NULL
costimulation	NULL
involve	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
different	NULL
cell	NULL
systems	NULL
.	NULL

The	NULL
vast	NULL
majority	NULL
of	NULL
information	NULL
acquired	NULL
regarding	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
CD28	NULL
costimulation	NULL
has	NULL
been	NULL
obtained	NULL
from	NULL
experiments	NULL
using	NULL
human	NULL
and	NULL
murine	NULL
T	NULL
cell	NULL
lines	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
,	NULL
although	NULL
primary	NULL
T	NULL
cells	NULL
must	NULL
be	NULL
suboptimally	NULL
activated	NULL
with	NULL
PHA	NULL
in	NULL
order	NULL
to	NULL
achieve	NULL
transfection	NULL
competency	NULL
,	NULL
no	NULL
transcription	NULL
is	NULL
detectable	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
stimulation	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
indicated	NULL
that	NULL
regulation	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
differs	NULL
from	NULL
that	NULL
observed	NULL
in	NULL
tumor	NULL
T	NULL
cell	NULL
lines	NULL
.	NULL

For	NULL
example	NULL
,	NULL
NF-AT	NULL
sites	NULL
are	NULL
much	NULL
less	NULL
important	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
than	NULL
in	NULL
tumor	NULL
T	NULL
cell	NULL
lines	NULL
,	NULL
while	NULL
the	NULL
proximal	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
are	NULL
of	NULL
critical	NULL
importance	NULL
(	NULL
23	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
expression	NULL
of	NULL
an	NULL
IL-2	NULL
promoter	NULL
construct	NULL
mutated	NULL
at	NULL
the	NULL
CD28RE	NULL
site	NULL
and	NULL
transfected	NULL
into	NULL
primary	NULL
T	NULL
cells	NULL
resulted	NULL
in	NULL
reduced	NULL
expression	NULL
following	NULL
CD28	NULL
costimulation	NULL
;	NULL
however	NULL
,	NULL
mutation	NULL
of	NULL
this	NULL
site	NULL
did	NULL
not	NULL
affect	NULL
expression	NULL
following	NULL
CD2	NULL
activation	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
appearance	NULL
of	NULL
components	NULL
of	NULL
cis-regulatory	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
CD28RE	NULL
,	NULL
particularly	NULL
c-rel	NULL
,	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
closely	NULL
linked	NULL
with	NULL
CD28	NULL
costimulation	NULL
in	NULL
tumor	NULL
T	NULL
cell	NULL
lines	NULL
,	NULL
which	NULL
has	NULL
not	NULL
been	NULL
the	NULL
case	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
(	NULL
31	NULL
)	NULL
.	NULL

In	NULL
PBMC	NULL
following	NULL
PMA	NULL
stimulation	NULL
alone	NULL
,	NULL
c-rel	NULL
binding	NULL
to	NULL
the	NULL
CD28RE	NULL
was	NULL
detected	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
secretion	NULL
.	NULL

While	NULL
costimulation	NULL
by	NULL
CD28	NULL
did	NULL
result	NULL
in	NULL
enhanced	NULL
c-rel	NULL
binding	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
CD28	NULL
cis-binding	NULL
factors	NULL
in	NULL
cells	NULL
not	NULL
actively	NULL
expressing	NULL
IL-2	NULL
indicate	NULL
that	NULL
binding	NULL
to	NULL
the	NULL
CD28RE	NULL
is	NULL
not	NULL
exclusively	NULL
a	NULL
response	NULL
to	NULL
CD28	NULL
costimulation	NULL
(	NULL
31	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
finding	NULL
of	NULL
CD28-independent	NULL
transcriptional	NULL
activation	NULL
was	NULL
reported	NULL
following	NULL
CD3	NULL
plus	NULL
PMA	NULL
costimulation	NULL
and	NULL
reporter	NULL
gene	NULL
transactivation	NULL
of	NULL
a	NULL
CD28RE	NULL
promoter-reporter	NULL
construct	NULL
(	NULL
32	NULL
)	NULL
.	NULL

The	NULL
CD28RE	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
bind	NULL
B-like	NULL
proteins	NULL
,	NULL
and	NULL
CD28	NULL
costimulation	NULL
results	NULL
in	NULL
the	NULL
rapid	NULL
down-regulation	NULL
of	NULL
IxBa	NULL
and	NULL
concordant	NULL
translocation	NULL
of	NULL
c-rel	NULL
to	NULL
the	NULL
nucleus	NULL
in	NULL
PBMC	NULL
and	NULL
T	NULL
cell	NULL
lines	NULL
(	NULL
33	NULL
)	NULL
.	NULL

These	NULL
reports	NULL
conflict	NULL
with	NULL
our	NULL
observations	NULL
of	NULL
LPMC	NULL
costimulated	NULL
with	NULL
CD28	NULL
.	NULL

While	NULL
CD2	NULL
activation	NULL
modestly	NULL
increases	NULL
expression	NULL
of	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
CD28RE	NULL
,	NULL
CD28	NULL
costimulation	NULL
did	NULL
not	NULL
further	NULL
enhance	NULL
this	NULL
effect	NULL
.	NULL

Likewise	NULL
,	NULL
a	NULL
rapid	NULL
decrease	NULL
in	NULL
the	NULL
level	NULL
of	NULL
IxBa	NULL
was	NULL
detected	NULL
following	NULL
CD2	NULL
activation	NULL
,	NULL
however	NULL
,	NULL
no	NULL
further	NULL
or	NULL
sustained	NULL
decrease	NULL
was	NULL
detected	NULL
following	NULL
CD28	NULL
costimulation	NULL
.	NULL

Recent	NULL
evidence	NULL
suggests	NULL
that	NULL
the	NULL
CD28RE	NULL
does	NULL
not	NULL
function	NULL
as	NULL
a	NULL
discrete	NULL
element	NULL
but	NULL
rather	NULL
is	NULL
part	NULL
of	NULL
a	NULL
composite	NULL
RE/AP	NULL
site	NULL
,	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
6628	NULL
consisting	NULL
of	NULL
the	NULL
CD28RE	NULL
and	NULL
the	NULL
adjacent	NULL
AP-1	NULL
(	NULL
24	NULL
)	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
AP-1	NULL
involvement	NULL
in	NULL
regulation	NULL
of	NULL
c-rel	NULL
activity	NULL
and	NULL
IL-2	NULL
expression	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
finding	NULL
that	NULL
overexpression	NULL
of	NULL
c-rel	NULL
greatly	NULL
up-regulates	NULL
AP-1	NULL
expression	NULL
.	NULL

Not	NULL
only	NULL
is	NULL
binding	NULL
to	NULL
the	NULL
consensus	NULL
AP-1	NULL
sequence	NULL
increased	NULL
,	NULL
but	NULL
more	NULL
importantly	NULL
,	NULL
the	NULL
binding	NULL
to	NULL
the	NULL
nonconsensus	NULL
AP-1	NULL
sequence	NULL
immediately	NULL
adjacent	NULL
to	NULL
the	NULL
CD28RE	NULL
is	NULL
enhanced	NULL
as	NULL
well	NULL
(	NULL
34	NULL
)	NULL
.	NULL

The	NULL
requirement	NULL
for	NULL
a	NULL
composite	NULL
regulatory	NULL
site	NULL
is	NULL
further	NULL
supported	NULL
by	NULL
studies	NULL
demonstrating	NULL
that	NULL
the	NULL
HIV	NULL
tax	NULL
responsiveness	NULL
region	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
requires	NULL
both	NULL
the	NULL
CD28RE	NULL
and	NULL
the	NULL
adjacent	NULL
AP-1	NULL
regions	NULL
(	NULL
35	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
CD28RE	NULL
might	NULL
be	NULL
functionally	NULL
redundant	NULL
and	NULL
thereby	NULL
mediate	NULL
more	NULL
than	NULL
one	NULL
signaling	NULL
pathway	NULL
.	NULL

Our	NULL
data	NULL
suggest	NULL
that	NULL
,	NULL
at	NULL
least	NULL
in	NULL
regard	NULL
to	NULL
the	NULL
composite	NULL
RE/AP	NULL
,	NULL
peripheral	NULL
T	NULL
cells	NULL
behave	NULL
in	NULL
a	NULL
manner	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
T	NULL
cell	NULL
lines	NULL
while	NULL
transactivation	NULL
of	NULL
LP	NULL
T	NULL
cell	NULL
entails	NULL
unique	NULL
cis-regulatory	NULL
elements	NULL
.	NULL

It	NULL
is	NULL
quite	NULL
likely	NULL
that	NULL
the	NULL
cell	NULL
system	NULL
as	NULL
well	NULL
as	NULL
the	NULL
mode	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
may	NULL
influence	NULL
regulation	NULL
of	NULL
IL-2	NULL
gene	NULL
transcription	NULL
.	NULL

Interpretation	NULL
of	NULL
the	NULL
data	NULL
obtained	NULL
through	NULL
functional	NULL
expression	NULL
of	NULL
transfected	NULL
IL-2	NULL
promoter-reporter	NULL
construct	NULL
are	NULL
subject	NULL
to	NULL
an	NULL
important	NULL
bias	NULL
in	NULL
that	NULL
they	NULL
are	NULL
reflective	NULL
of	NULL
the	NULL
sequences	NULL
selected	NULL
,	NULL
while	NULL
elements	NULL
residing	NULL
outside	NULL
of	NULL
the	NULL
chosen	NULL
promoter	NULL
region	NULL
would	NULL
not	NULL
be	NULL
detected	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
transfection	NULL
experiments	NULL
were	NULL
carried	NULL
out	NULL
utilizing	NULL
a	NULL
600-bp	NULL
IL-2	NULL
promoter	NULL
construct	NULL
that	NULL
encompasses	NULL
the	NULL
highly	NULL
conserved	NULL
region	NULL
defined	NULL
as	NULL
the	NULL
critical	NULL
IL-2	NULL
promoter	NULL
element	NULL
.	NULL

However	NULL
,	NULL
DNase	NULL
I	NULL
hypersensitive	NULL
sites	NULL
have	NULL
been	NULL
identified	NULL
within	NULL
3	NULL
kb	NULL
upstream	NULL
of	NULL
the	NULL
IL-2	NULL
transcriptional	NULL
start	NULL
site	NULL
(	NULL
36	NULL
,	NULL
37	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
the	NULL
EMSA	NULL
analyses	NULL
were	NULL
conducted	NULL
utilizing	NULL
the	NULL
well-studied	NULL
CD28RE/AP-1	NULL
composite	NULL
element	NULL
.	NULL

Likewise	NULL
,	NULL
transcriptional	NULL
run-on	NULL
assays	NULL
,	NULL
although	NULL
the	NULL
methods	NULL
of	NULL
choice	NULL
in	NULL
analyzing	NULL
fluctuations	NULL
in	NULL
the	NULL
rate	NULL
of	NULL
transcription	NULL
initiation	NULL
are	NULL
susceptible	NULL
to	NULL
attenuation	NULL
through	NULL
DNA	NULL
sequences	NULL
within	NULL
a	NULL
gene	NULL
(	NULL
37	NULL
)	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
sequences	NULL
other	NULL
than	NULL
those	NULL
studied	NULL
might	NULL
play	NULL
a	NULL
role	NULL
in	NULL
transcriptional	NULL
regulation	NULL
following	NULL
CD28	NULL
costimulation	NULL
in	NULL
LPMC	NULL
,	NULL
albeit	NULL
unlikely	NULL
considering	NULL
that	NULL
inhibitory	NULL
elements	NULL
have	NULL
been	NULL
reported	NULL
residing	NULL
upstream	NULL
of	NULL
the	NULL
600-bp	NULL
promoter	NULL
element	NULL
.	NULL

Studies	NULL
are	NULL
underway	NULL
to	NULL
identify	NULL
other	NULL
regions	NULL
that	NULL
might	NULL
respond	NULL
to	NULL
CD28	NULL
costimulation	NULL
and	NULL
regulate	NULL
transcriptional	NULL
activation	NULL
in	NULL
LPMC	NULL
.	NULL

An	NULL
increase	NULL
in	NULL
mRNA	NULL
stability	NULL
in	NULL
PBMC	NULL
and	NULL
T	NULL
cell	NULL
tumor	NULL
cell	NULL
lines	NULL
following	NULL
CD28	NULL
costimulation	NULL
has	NULL
been	NULL
reported	NULL
for	NULL
numerous	NULL
cytokines	NULL
,	NULL
including	NULL
IL-2	NULL
,	NULL
IFN-y	NULL
,	NULL
GM-CSF	NULL
,	NULL
and	NULL
TNF-a	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Little	NULL
is	NULL
known	NULL
about	NULL
posttranscriptional	NULL
regulation	NULL
of	NULL
IL-2	NULL
expression	NULL
,	NULL
however	NULL
,	NULL
several	NULL
cytokines	NULL
and	NULL
transiently	NULL
expressed	NULL
proto-oncogenes	NULL
contain	NULL
one	NULL
or	NULL
more	NULL
highly	NULL
conserved	NULL
AUUUA	NULL
motifs	NULL
in	NULL
the	NULL
3'-UT	NULL
region	NULL
of	NULL
their	NULL
mRNA	NULL
(	NULL
12	NULL
)	NULL
.	NULL

These	NULL
consensus	NULL
elements	NULL
are	NULL
determinants	NULL
for	NULL
rapid	NULL
degradation	NULL
,	NULL
probably	NULL
through	NULL
interaction	NULL
with	NULL
specific	NULL
proteins	NULL
that	NULL
can	NULL
be	NULL
cross-linked	NULL
to	NULL
these	NULL
AU-rich	NULL
domains	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Nonetheless	NULL
,	NULL
while	NULL
CD28	NULL
costimulation	NULL
results	NULL
in	NULL
the	NULL
stabilization	NULL
of	NULL
IL-2	NULL
mRNA	NULL
,	NULL
the	NULL
proto-oncogenes	NULL
c-fos	NULL
,	NULL
and	NULL
c-myc	NULL
were	NULL
not	NULL
further	NULL
stabilized	NULL
,	NULL
despite	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
mRNAs	NULL
of	NULL
these	NULL
factors	NULL
possess	NULL
multiple	NULL
AUUUA	NULL
sequences	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Recent	NULL
studies	NULL
of	NULL
regulation	NULL
of	NULL
IL-2	NULL
mRNA	NULL
stability	NULL
in	NULL
T	NULL
cell	NULL
lines	NULL
indicate	NULL
that	NULL
multiple	NULL
mechanisms	NULL
regulate	NULL
IL-2	NULL
mRNA	NULL
stability	NULL
and	NULL
suggest	NULL
that	NULL
both	NULL
5	NULL
'	NULL
as	NULL
well	NULL
as	NULL
3	NULL
'	NULL
sequences	NULL
within	NULL
the	NULL
untranslated	NULL
region	NULL
of	NULL
the	NULL
IL-2	NULL
mRNA	NULL
are	NULL
critical	NULL
for	NULL
stabilization	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
in	NULL
activated	NULL
T	NULL
cell	NULL
lines	NULL
,	NULL
activation	NULL
of	NULL
the	NULL
c-jun	NULL
amino-terminal	NULL
kinase	NULL
is	NULL
involved	NULL
in	NULL
IL-2	NULL
mRNA	NULL
transcription	NULL
and	NULL
stabilization	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
would	NULL
appear	NULL
that	NULL
multiple	NULL
posttranscriptional	NULL
mechanisms	NULL
other	NULL
than	NULL
the	NULL
AUUUA	NULL
motifs	NULL
regulate	NULL
IL-2	NULL
mRNA	NULL
stability	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
the	NULL
studies	NULL
presented	NULL
here	NULL
show	NULL
that	NULL
regulation	NULL
of	NULL
IL-2	NULL
expression	NULL
in	NULL
LPMC	NULL
and	NULL
LP-like	NULL
T	NULL
cells	NULL
differs	NULL
from	NULL
that	NULL
observed	NULL
in	NULL
PBMC	NULL
.	NULL

CD28	NULL
costimulation	NULL
of	NULL
LPMC	NULL
increased	NULL
IL-2	NULL
TRANSACTIVATION	NULL
OF	NULL
THE	NULL
IL-2	NULL
PROMOTER	NULL
production	NULL
paralleled	NULL
by	NULL
increased	NULL
expression	NULL
of	NULL
IL-2	NULL
mRNA	NULL
due	NULL
in	NULL
part	NULL
to	NULL
enhanced	NULL
IL-2	NULL
mRNA	NULL
stability	NULL
.	NULL

However	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
CD28-mediated	NULL
transcriptional	NULL
activation	NULL
in	NULL
PBMC	NULL
,	NULL
EMSA	NULL
analysis	NULL
revealed	NULL
that	NULL
CD28	NULL
coligation	NULL
of	NULL
LPMC	NULL
did	NULL
not	NULL
augment	NULL
binding	NULL
of	NULL
trans-acting	NULL
factors	NULL
to	NULL
the	NULL
CD28RE	NULL
or	NULL
alterations	NULL
in	NULL
IxBa	NULL
or	NULL
IBB	NULL
levels	NULL
.	NULL

Although	NULL
CD2-enhanced	NULL
IL-2	NULL
secretion	NULL
is	NULL
reflected	NULL
by	NULL
transactivation	NULL
of	NULL
IL-2	NULL
promoter	NULL
reporter	NULL
constructs	NULL
transfected	NULL
into	NULL
LPMC	NULL
,	NULL
there	NULL
was	NULL
no	NULL
enhanced	NULL
CD28-mediated	NULL
promoter	NULL
activation	NULL
following	NULL
coligation	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
these	NULL
studies	NULL
represent	NULL
the	NULL
first	NULL
reports	NULL
of	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
RE/AP	NULL
composite	NULL
element	NULL
in	NULL
response	NULL
to	NULL
CD2	NULL
stimulation	NULL
.	NULL

These	NULL
observations	NULL
suggest	NULL
a	NULL
biological	NULL
significance	NULL
for	NULL
different	NULL
mechanisms	NULL
of	NULL
IL-2	NULL
gene	NULL
activation	NULL
in	NULL
initiation	NULL
and	NULL
maintenance	NULL
of	NULL
cytokine	NULL
production	NULL
in	NULL
the	NULL
mucosa	NULL
.	NULL

Furthermore	NULL
,	NULL
these	NULL
results	NULL
strengthen	NULL
the	NULL
use	NULL
of	NULL
LP-like	NULL
T	NULL
cells	NULL
as	NULL
a	NULL
model	NULL
for	NULL
LP	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
the	NULL
analysis	NULL
of	NULL
mucosal	NULL
cytokine	NULL
gene	NULL
regulation	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Rachel	NULL
Kramer	NULL
for	NULL
providing	NULL
cultured	NULL
LPMC	NULL
and	NULL
PBMC	NULL
and	NULL
Dr.	NULL
Howard	NULL
Young	NULL
for	NULL
his	NULL
helpful	NULL
discussions	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
M.	NULL
R.	NULL
Bush	NULL
,	NULL
J.	NULL
G.	NULL
Morgan	NULL
,	NULL
A.	NULL
Weiss	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabiree	NULL
.	NULL

1987	NULL
.	NULL

A	NULL
275	NULL
basepair	NULL
fragment	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
enhances	NULL
expression	NULL
from	NULL
a	NULL
heterologous	NULL
promoter	NULL
in	NULL
response	NULL
to	NULL
signals	NULL
from	NULL
the	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

165:395	NULL
.	NULL

2	NULL
.	NULL

Serfling	NULL
,	NULL
E.	NULL
,	NULL
R.	NULL
Barthelmas	NULL
,	NULL
I.	NULL
Pfeuffer	NULL
,	NULL
B.	NULL
Schenk	NULL
,	NULL
S.	NULL
Zarius	NULL
,	NULL
R.	NULL
Swoboda	NULL
,	NULL
F.	NULL
Mercurio	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1989	NULL
.	NULL

Ubiquitous	NULL
and	NULL
lymphocyte-specific	NULL
factors	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
mouse	NULL
interleukin	NULL
2	NULL
gene	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:465	NULL
.	NULL

3	NULL
.	NULL

Efrat	NULL
,	NULL
S.	NULL
,	NULL
S.	NULL
Pilo	NULL
,	NULL
and	NULL
R.	NULL
Kaempfer	NULL
.	NULL

1982	NULL
.	NULL

Kinetics	NULL
of	NULL
induction	NULL
and	NULL
molecular	NULL
size	NULL
of	NULL
mRNAs	NULL
encoding	NULL
human	NULL
interleukin-2	NULL
and	NULL
y-interferon	NULL
.	NULL

Nature	NULL
297:236	NULL
.	NULL

4	NULL
.	NULL

Efrat	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
R.	NULL
Kaempfer	NULL
.	NULL

1984	NULL
.	NULL

Control	NULL
of	NULL
biologically	NULL
active	NULL
interleukin	NULL
2	NULL
messenger	NULL
RNA	NULL
formation	NULL
in	NULL
induced	NULL
human	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
81:2601	NULL
.	NULL

5	NULL
.	NULL

Gerez	NULL
,	NULL
L.	NULL
,	NULL
G.	NULL
Arad	NULL
,	NULL
S.	NULL
Efrat	NULL
,	NULL
M.	NULL
Ketzinel	NULL
,	NULL
and	NULL
R.	NULL
Kacmpfer	NULL
.	NULL

1995	NULL
.	NULL

Post-tran-scriptional	NULL
regulation	NULL
of	NULL
human	NULL
interleukin-2	NULL
gene	NULL
expression	NULL
at	NULL
processing	NULL
of	NULL
precursor	NULL
transcripts	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:19569	NULL
.	NULL

6	NULL
.	NULL

Hansen	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
P.	NULL
J.	NULL
Martin	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Nowinski	NULL
.	NULL

1980	NULL
.	NULL

Monoclonal	NULL
antibodies	NULL
identifying	NULL
a	NULL
novel	NULL
T	NULL
cell	NULL
antigen	NULL
and	NULL
Ta	NULL
antigens	NULL
of	NULL
human	NULL
lymphocytes	NULL
.	NULL

Immu-nogenetics	NULL
10:247	NULL
.	NULL

7	NULL
.	NULL

June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Ledbetter	NULL
,	NULL
M.	NULL
M.	NULL
Gillespie	NULL
,	NULL
T.	NULL
Lindsten	NULL
,	NULL
and	NULL
C.	NULL
B.	NULL
Thompson	NULL
.	NULL

1987	NULL
.	NULL

T	NULL
cell	NULL
proliferation	NULL
involving	NULL
the	NULL
CD28	NULL
pathway	NULL
is	NULL
associated	NULL
with	NULL
cyclos-porine-resistant	NULL
interleukin	NULL
2	NULL
gene	NULL
expression	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7:4472	NULL
.	NULL

8	NULL
.	NULL

Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Irving	NULL
,	NULL
G.	NULL
R.	NULL
Crabtree	NULL
,	NULL
and	NULL
A.	NULL
Weiss	NULL
.	NULL

1991	NULL
.	NULL

Regulation	NULL
of	NULL
interleukin-2	NULL
gene	NULL
enhancer	NULL
activity	NULL
by	NULL
the	NULL
T	NULL
cell	NULL
accessory	NULL
molecule	NULL
CD28	NULL
.	NULL

Science	NULL
251:313	NULL
.	NULL

9	NULL
.	NULL

Ghosh	NULL
,	NULL
P.	NULL
,	NULL
T.	NULL
Tan	NULL
,	NULL
N.	NULL
R.	NULL
Rice	NULL
,	NULL
A.	NULL
Sica	NULL
,	NULL
and	NULL
H.	NULL
A	NULL
.	NULL

Young	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
interleukin	NULL
2	NULL
CD28-responsive	NULL
complex	NULL
contains	NULL
at	NULL
least	NULL
three	NULL
members	NULL
of	NULL
the	NULL
NF-kB	NULL
fam-ily	NULL
:	NULL
c-Rel	NULL
,	NULL
p50	NULL
,	NULL
and	NULL
p65	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:1696	NULL
.	NULL

10	NULL
.	NULL

Henkel	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Machleidt	NULL
,	NULL
I.	NULL
Alkalay	NULL
,	NULL
M.	NULL
Kronke	NULL
,	NULL
Y.	NULL
Ben-Neriah	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Bacuerle	NULL
.	NULL

1993	NULL
.	NULL

Rapid	NULL
proteolysis	NULL
of	NULL
IxBa	NULL
is	NULL
necessary	NULL
for	NULL
activation	NULL
of	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Nature	NULL
365:182	NULL
.	NULL

11	NULL
.	NULL

Liou	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1993	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
NE-B/rel	NULL
transcription	NULL
factor	NULL
and	NULL
IB	NULL
inhibitor	NULL
system	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

5:477	NULL
.	NULL

12	NULL
.	NULL

Caput	NULL
,	NULL
D.	NULL
,	NULL
B.	NULL
Beutler	NULL
,	NULL
K.	NULL
Hartog	NULL
,	NULL
R.	NULL
Thayer	NULL
,	NULL
S.	NULL
Brown-Shiner	NULL
,	NULL
and	NULL
A.	NULL
Cerami	NULL
.	NULL

1986	NULL
.	NULL

Identification	NULL
of	NULL
common	NULL
nucleotide	NULL
sequence	NULL
in	NULL
the	NULL
3	NULL
'	NULL
-untranslated	NULL
region	NULL
of	NULL
mRNA	NULL
molecules	NULL
specifying	NULL
inflammatory	NULL
mediators	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83:1670	NULL
.	NULL

13	NULL
.	NULL

Lindsten	NULL
,	NULL
T.	NULL
,	NULL
C.	NULL
H.	NULL
June	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Ledbetter	NULL
,	NULL
G.	NULL
Stella	NULL
,	NULL
and	NULL
C.	NULL
B.	NULL
Thompson	NULL
.	NULL

1989	NULL
.	NULL

Regulation	NULL
of	NULL
lymphokine	NULL
messenger	NULL
RNA	NULL
stability	NULL
by	NULL
a	NULL
surface-mediated	NULL
T	NULL
cell	NULL
activation	NULL
pathway	NULL
.	NULL

Science	NULL
244:339	NULL
.	NULL

14	NULL
.	NULL

Sachs	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

1993	NULL
.	NULL

Messenger	NULL
RNA	NULL
degradation	NULL
in	NULL
eukaryotes	NULL
.	NULL

Cell	NULL
74:413	NULL
.	NULL

15	NULL
.	NULL

Pirzer	NULL
,	NULL
U.	NULL
C.	NULL
,	NULL
G.	NULL
Schiirmann	NULL
,	NULL
S.	NULL
Post	NULL
,	NULL
M.	NULL
Betzler	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Meuer	NULL
.	NULL

1990	NULL
.	NULL

Differential	NULL
responsiveness	NULL
to	NULL
CD3-Ti	NULL
vs.	NULL
CD2-dependent	NULL
activation	NULL
of	NULL
human	NULL
intestinal	NULL
T-lymphocytes	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

20:2339	NULL
.	NULL

16	NULL
.	NULL

Targan	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
R.	NULL
L.	NULL
Deem	NULL
,	NULL
M.	NULL
Liu	NULL
,	NULL
S.	NULL
Wang	NULL
,	NULL
and	NULL
A.	NULL
Nel	NULL
.	NULL

1995	NULL
.	NULL

Definition	NULL
of	NULL
a	NULL
lamina	NULL
propria	NULL
T	NULL
cell	NULL
responsive	NULL
state	NULL
:	NULL
enhanced	NULL
cytokine	NULL
responsiveness	NULL
of	NULL
T	NULL
cells	NULL
stimulated	NULL
through	NULL
the	NULL
CD2	NULL
pathway	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:664	NULL
.	NULL

17	NULL
.	NULL

Boirivant	NULL
,	NULL
M.	NULL
,	NULL
I.	NULL
J.	NULL
Fuss	NULL
,	NULL
C.	NULL
Fiocchi	NULL
,	NULL
J.	NULL
S.	NULL
Klein	NULL
,	NULL
S.	NULL
A	NULL
.	NULL

Strong	NULL
,	NULL
and	NULL
W.	NULL
Strober	NULL
.	NULL

1996	NULL
.	NULL

Hypoproliferative	NULL
human	NULL
lamina	NULL
propria	NULL
T	NULL
cells	NULL
retain	NULL
the	NULL
capacity	NULL
to	NULL
secrete	NULL
lymphokines	NULL
when	NULL
stimulated	NULL
via	NULL
CD2/CD28	NULL
signaling	NULL
pathway	NULL
.	NULL

Proc	NULL
.	NULL

As-soc	NULL
.	NULL

Am	NULL
.	NULL

Physicians	NULL
108:55	NULL
.	NULL

18	NULL
.	NULL

Mulin	NULL
,	NULL
G.	NULL
,	NULL
Z.	NULL
R.	NULL
Maycon	NULL
,	NULL
L.	NULL
Braun-Elwert	NULL
,	NULL
R.	NULL
Cerchia	NULL
,	NULL
S.	NULL
P.	NULL
James	NULL
,	NULL
S.	NULL
Katz	NULL
,	NULL
G.	NULL
Weissman	NULL
,	NULL
M.	NULL
J.	NULL
McKinley	NULL
,	NULL
and	NULL
S.	NULL
E.	NULL
Fisher	NULL
.	NULL

1996	NULL
.	NULL

Inflammatory	NULL
bowel	NULL
disease	NULL
mucosal	NULL
biopsies	NULL
have	NULL
specialized	NULL
lymphokine	NULL
mRNA	NULL
profiles	NULL
.	NULL

Inflamm	NULL
.	NULL

Bowel	NULL
Dis	NULL
.	NULL

2:16	NULL
.	NULL

19	NULL
.	NULL

Gonsky	NULL
,	NULL
R.	NULL
,	NULL
R.	NULL
L.	NULL
Deem	NULL
,	NULL
C.	NULL
C.	NULL
W.	NULL
Hughes	NULL
,	NULL
and	NULL
S.	NULL
R.	NULL
Targan	NULL
.	NULL

1998	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
CD2	NULL
pathway	NULL
in	NULL
lamina	NULL
propria	NULL
T	NULL
cells	NULL
up-regulates	NULL
functionally	NULL
active	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

AP-1	NULL
binding	NULL
to	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
resulting	NULL
in	NULL
messenger	NULL
RNA	NULL
transcription	NULL
on	NULL
IL-2	NULL
secretion	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

160:4914	NULL
.	NULL

Shanahan	NULL
,	NULL
F.	NULL
,	NULL
M.	NULL
Brogan	NULL
,	NULL
and	NULL
S.	NULL
R.	NULL
Targan	NULL
.	NULL

1987	NULL
.	NULL

Human	NULL
mucosal	NULL
cytotoxic	NULL
effector	NULL
cells	NULL
.	NULL

Gastroenterology	NULL
92:1951	NULL
.	NULL

Gillis	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
M.	NULL
Ferm	NULL
,	NULL
O.	NULL
Winny	NULL
,	NULL
and	NULL
K.	NULL
A.	NULL
Smith	NULL
.	NULL

1978	NULL
.	NULL

T	NULL
cell	NULL
growth	NULL
factor	NULL
:	NULL
parameters	NULL
of	NULL
production	NULL
and	NULL
quantitative	NULL
microassay	NULL
for	NULL
activity	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

120:2027	NULL
.	NULL

Ausubel	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
R.	NULL
Brent	NULL
,	NULL
R.	NULL
E.	NULL
Kingston	NULL
,	NULL
D.	NULL
D.	NULL
Moore	NULL
,	NULL
J.	NULL
G.	NULL
Seidman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Smith	NULL
,	NULL
and	NULL
K.	NULL
Struhl	NULL
,	NULL
eds	NULL
.	NULL

1990	NULL
.	NULL

Current	NULL
Protocols	NULL
in	NULL
Molecular	NULL
Biology	NULL
,	NULL
Greene	NULL
Publishing	NULL
Associates	NULL
and	NULL
Wiley-Interscience	NULL
,	NULL
New	NULL
York	NULL
,	NULL
pp	NULL
.	NULL

4.10.1-4.10.8	NULL
.	NULL

Hughes	NULL
,	NULL
C.	NULL
C.	NULL
W.	NULL
,	NULL
and	NULL
J.	NULL
S.	NULL
Pober	NULL
.	NULL

1996	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
interleukin-2	NULL
gene	NULL
in	NULL
normal	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:5369	NULL
.	NULL

Shapiro	NULL
,	NULL
V.	NULL
S.	NULL
,	NULL
K.	NULL
E.	NULL
Truitt	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Imboden	NULL
,	NULL
and	NULL
A.	NULL
Weiss	NULL
.	NULL

1997	NULL
.	NULL

CD28	NULL
mediates	NULL
transcriptional	NULL
upregulation	NULL
of	NULL
the	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
promoter	NULL
through	NULL
a	NULL
composite	NULL
element	NULL
containing	NULL
the	NULL
CD28RE	NULL
and	NULL
NF-IL-2B	NULL
AP-1	NULL
sites	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

17:4051	NULL
.	NULL

Angel	NULL
,	NULL
P.	NULL
,	NULL
M.	NULL
Imagawa	NULL
,	NULL
R.	NULL
Chiu	NULL
,	NULL
B.	NULL
Stein	NULL
,	NULL
R.	NULL
J.	NULL
Imbra	NULL
,	NULL
H.	NULL
J.	NULL
Rahmsdorf	NULL
,	NULL
C.	NULL
Jonat	NULL
,	NULL
P.	NULL
Herrlich	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1987	NULL
.	NULL

Phorbol	NULL
ester-inducible	NULL
genes	NULL
contain	NULL
a	NULL
common	NULL
cis	NULL
element	NULL
recognized	NULL
by	NULL
a	NULL
TPA-modulated	NULL
frans-acting	NULL
factor	NULL
.	NULL

Cell	NULL
49:729	NULL
.	NULL

Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
M.	NULL
Geerts	NULL
,	NULL
and	NULL
L.	NULL
A.	NULL
Aardon	NULL
.	NULL

1991	NULL
.	NULL

Activation	NULL
of	NULL
interleukin-2	NULL
gene	NULL
transcription	NULL
via	NULL
the	NULL
T	NULL
cell	NULL
surface	NULL
molecule	NULL
CD28	NULL
is	NULL
mediated	NULL
through	NULL
the	NULL
NF-B-like	NULL
response	NULL
element	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266:14179	NULL
.	NULL

Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
A.	NULL
Weiss	NULL
.	NULL

1992	NULL
.	NULL

Regulation	NULL
of	NULL
T	NULL
cell	NULL
lymphokine	NULL
gene	NULL
transcription	NULL
by	NULL
the	NULL
accessory	NULL
molecule	NULL
CD28	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:4357	NULL
.	NULL

Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
M.	NULL
E.	NULL
Newton	NULL
,	NULL
and	NULL
A.	NULL
Weiss	NULL
.	NULL

1992	NULL
.	NULL

CD28	NULL
and	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
signal	NULL
transduction	NULL
coordinately	NULL
regulate	NULL
interleukin	NULL
2	NULL
gene	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
superantigen	NULL
stimulation	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175:1131	NULL
.	NULL

Finn	NULL
,	NULL
P.	NULL
W.	NULL
,	NULL
H.	NULL
He	NULL
,	NULL
Y.	NULL
Wang	NULL
,	NULL
Z.	NULL
Wang	NULL
,	NULL
G.	NULL
Guan	NULL
,	NULL
J.	NULL
Listman	NULL
,	NULL
and	NULL
D.	NULL
L.	NULL
Perkins	NULL
.	NULL

1997	NULL
.	NULL

Synergistic	NULL
induction	NULL
of	NULL
CTLA-4	NULL
expression	NULL
by	NULL
costimulation	NULL
with	NULL
TCR	NULL
30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

6629	NULL
plus	NULL
CD28	NULL
signals	NULL
mediated	NULL
by	NULL
increased	NULL
transcription	NULL
and	NULL
messenger	NULL
ribonucleic	NULL
acid	NULL
stability	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:4074	NULL
.	NULL

Umlauf	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
B.	NULL
Beverly	NULL
,	NULL
O.	NULL
Lantz	NULL
,	NULL
and	NULL
R.	NULL
H.	NULL
Schwartz	NULL
.	NULL

1995	NULL
.	NULL

Regulation	NULL
of	NULL
interleukin	NULL
2	NULL
gene	NULL
expression	NULL
by	NULL
CD28	NULL
costimulation	NULL
in	NULL
mouse	NULL
T	NULL
cell	NULL
clones	NULL
:	NULL
both	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
RNAs	NULL
are	NULL
regulated	NULL
with	NULL
complex	NULL
kinetics	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

15:3197	NULL
.	NULL

Bryan	NULL
,	NULL
R.	NULL
G.	NULL
,	NULL
Y.	NULL
Li	NULL
,	NULL
J.	NULL
Lai	NULL
,	NULL
M.	NULL
Van	NULL
,	NULL
N.	NULL
R.	NULL
Rice	NULL
,	NULL
R.	NULL
R.	NULL
Rich	NULL
,	NULL
and	NULL
T.	NULL
Tan	NULL
.	NULL

1994	NULL
.	NULL

Effect	NULL
of	NULL
CD28	NULL
signal	NULL
transduction	NULL
on	NULL
c-Rel	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:7933	NULL
.	NULL

Civil	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Geerts	NULL
,	NULL
I	NULL
.	NULL

A.	NULL
Aarden	NULL
,	NULL
and	NULL
C.	NULL
L.	NULL
Verweij	NULL
.	NULL

1992	NULL
.	NULL

Evidence	NULL
for	NULL
a	NULL
role	NULL
of	NULL
CD28RE	NULL
as	NULL
a	NULL
response	NULL
element	NULL
for	NULL
distinct	NULL
mitogenic	NULL
T	NULL
cell	NULL
activation	NULL
signals	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

22:3041	NULL
.	NULL

Beg	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Baldwin	NULL
,	NULL
Jr.	NULL
1993	NULL
.	NULL

The	NULL
IB	NULL
proteins	NULL
:	NULL
multifunctional	NULL
regulators	NULL
of	NULL
Rel/NF-	NULL
«	NULL
B	NULL
transcription	NULL
factors	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

7:2064	NULL
.	NULL

Shapiro	NULL
,	NULL
V.	NULL
S.	NULL
,	NULL
M.	NULL
N.	NULL
Mollenauer	NULL
,	NULL
W.	NULL
C.	NULL
Greene	NULL
,	NULL
and	NULL
A.	NULL
Weiss	NULL
.	NULL

1996.	NULL
c-Rel	NULL
regulation	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
may	NULL
be	NULL
mediated	NULL
through	NULL
activation	NULL
of	NULL
AP-1	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184:1663	NULL
.	NULL

Curtiss	NULL
,	NULL
V.	NULL
E.	NULL
,	NULL
R.	NULL
Smilde	NULL
and	NULL
K.	NULL
L.	NULL
McGuire	NULL
1996	NULL
.	NULL

Requirements	NULL
for	NULL
interleukin	NULL
2	NULL
promoter	NULL
transactivation	NULL
by	NULL
the	NULL
Tax	NULL
protein	NULL
of	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:3567	NULL
.	NULL

Novak	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
P.	NULL
M.	NULL
White	NULL
,	NULL
and	NULL
E.	NULL
V.	NULL
Rothenberg	NULL
.	NULL

1990	NULL
.	NULL

Regulatory	NULL
anatomy	NULL
of	NULL
the	NULL
murine	NULL
terminal	NULL
kinase	NULL
pathway	NULL
interleukin-2	NULL
gene	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

18:4523	NULL
.	NULL

Wright	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Bishop	NULL
.	NULL

1989	NULL
.	NULL

DNA	NULL
sequences	NULL
that	NULL
mediate	NULL
attenuation	NULL
of	NULL
transcription	NULL
from	NULL
mouse	NULL
protooncogene	NULL
myc	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:505	NULL
.	NULL

Sachs	NULL
,	NULL
A	NULL
.	NULL

1993	NULL
.	NULL

Messenger	NULL
RNA	NULL
degradation	NULL
in	NULL
eukaryotes	NULL
.	NULL

Cell	NULL
74:413	NULL
.	NULL

Chen	NULL
C.	NULL
Y.	NULL
,	NULL
F.	NULL
D.	NULL
Gatto-Konczak	NULL
,	NULL
Z.	NULL
Wu	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1998	NULL
.	NULL

Stabilization	NULL
of	NULL
interleukin-2	NULL
mRNA	NULL
by	NULL
the	NULL
c-jun	NULL
NH	NULL
,	NULL
-terminal	NULL
kinase	NULL
pathway	NULL
.	NULL

Science	NULL
280	NULL
:	NULL
1945	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL

